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Abstract 
The evidence of exercise as adjuvant therapy option in cancer patients is increasing. Exercise 
constitutes a promising intervention to reduce treatment-related side-effects and to improve 
the rehabilitation process. Thus, there is growing interest in determining optimally targeted 
exercise prescriptions to maximize effects. However, few randomized controlled trials (RCTs) 
were conducted in haematological cancer patients during and after allogeneic stem cell 
transplantation (allo-HCT). Consequently, information regarding detailed exercise 
prescriptions and exercise response is lacking. Furthermore, a detailed description of 
adherence and related determinants would improve the understanding of exercise 
participation. 
The aim of this cumulative thesis is therefore to further close the indicated research gaps. 
Four manuscripts constitute the main body of this work. In these we (I) determined the 
individual training response dependent on physical performance level at baseline; we (II) 
described a large randomized controlled exercise intervention trial (PETRA study); we (III) 
compared recommended endurance exercise intensity classes to values obtained in 
haematological cancer patients; and we (IV) pictured adherence and its determinants in 
different treatment periods as well as the physical activity level of the control group within the 
PETRA study. Additionally, this thesis translates the findings into the current research context 
in the discussion part. The results will further refine exercise recommendations and exercise 
programs and will give important information for future study designs and data interpretation. 
(I) The first manuscript analysed data from 52 patients randomized to the experimental group 
in an RCT prior to, during and after allo-HCT. Results show that initially unfit patients had a 
significant better development of muscle strength and endurance performance during 
intervention period than the initially fit patients. For example, fit patients lost 31% of their 
knee extensor strength, whereas unfit patients lost only 1% (p=.03). For endurance capacity, 
the initially fit patients lost 4%, whereas the unfit patients gained 13% (p<.01). This finding is 
of major clinical relevance because exercise is often not recommended in deconditioned 
patients. 
(II) The second manuscript describes the PETRA study design. In this RCT, 256 patients prior 
to allogeneic stem cell transplantation will be included. The primary endpoint will be overall-
survival after two years. Secondary endpoints include physical performance, fatigue, quality 
of life, severity of side-effects and biomarkers. Gold-standard assessment procedures to assess 
physical performance and physical activity will be applied. The experimental group performs 
a partly supervised one-year combined (endurance and resistance training) moderate-intensity 
exercise program, the control group receives a comparable intervention, but with progressive 
muscle relaxation. The PETRA study will provide a large database to investigate the 
multidimensional effects of exercise on various clinical outcomes. 
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(III) In the third manuscript we compared for the first time commonly used endurance 
exercise intensity classes from the American College of Sports Medicine (ACSM) with 
cardiopulmonary exercise data obtained in a cancer population (106 patients prior to and 180 
days after allo-HCT). The analysis revealed that the ACSM’s exercise intensity 
recommendations for endurance training might not meet the targeted intensity classes in 
almost all classes (p<.05). The use of ACSM’s intensity classes would result in over- or 
under-estimation of endurance exercise intensity in allo-HCT patients. In order to give 
appropriate exercise prescriptions and to compare intensities between other studies, we 
provided tables with exercise intensity classes obtained in haematological cancer patients. 
Furthermore, we revealed that applying exercise intensity recommendations based on 
percentages of the commonly used equation 220-age did not provide appropriate intensities, 
and is therefore, not recommended. We expect that our results will further improve exercise 
prescription in haematological cancer patients. 
(IV) The fourth manuscript examined exercise adherence and physical activity in the control 
group (contamination) including the first 153 patients of the PETRA study. With 66-77% 
(89–199 min/ week) adherence was acceptable in all three studied periods (inpatient, 
outpatient up to day 100, day 100 up to day 180). Most important determinants for adherence 
were fatigue (p=.004), physical performance (p=.003) and prior exercise engagement (p=.010) 
in different studied periods. The models could explain 16%, 21% and 55% of variance 
respectively. Exercise contamination in the control group was evident in 54% (89% were 
walking on a regular basis). Determinants for exercise contamination were higher muscle 
strength (p=.025) and less fatigue (p=.050). Total variance explained was 29%. The 
recruitment of the first 153 patients in the PETRA study was excellent (73%), providing us 
with a representative sample of this challenging population. The results give important 
implications for personalized exercise programs and future data interpretation. 
In conclusion, this cumulative thesis gives essential information regarding questions on how 
to individually tailor exercise interventions for haematological cancer patients. Furthermore, 
the identification of determinants of both, adherence to exercise intervention and 
contamination of the control group will improve exercise programs and illustrate the need to 
pay more attention on physical activities performed in the control groups. 
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Kurzzusammenfassung 
Die Evidenz zu körperlichen Trainingsprogrammen als unterstützende Maßnahme bei 
Krebserkrankungen nimmt zu. Das körperliche Training stellt hierbei eine vielversprechende 
Intervention dar, um behandlungsbedingte Nebenwirkungen zu reduzieren und den 
Rehabilitationsprozess zu verbessern. Daher besteht zur optimalen Nutzung der positiven 
Effekte von körperlichem Training ein wachsendes Interesse darin, bestmögliche 
Trainingsempfehlungen für Patienten zu entwickeln. Im Bereich der Hämato-Onkologie 
wurden bisher jedoch nur wenige randomisierte, kontrollierte Studien (RCTs) mit Patienten 
während und nach einer allogenen Stammzelltransplantation (allo-HCT) durchgeführt. 
Informationen zu detaillierten Trainingsempfehlungen und Trainingsansprechen sind 
dementsprechend mangelhaft. Darüber hinaus würde eine detaillierte Beschreibung der 
Trainingsadhärenz und ihrer Determinanten helfen, die Akzeptanz des Trainings durch die 
Patienten zu verstehen. 
Das Ziel dieser kumulativen Thesis ist es, diese Forschungslücke weiter zu schließen. Vier 
Manuskripte bilden dabei den Hauptteil dieser Arbeit. Es wurde (I) das individuelle 
Trainingsansprechen in Abhängigkeit von der körperlichen Fitness vor der Intervention (zu 
Baseline) erfasst; (II) eine große randomisierte, kontrollierte Trainings-Interventionsstudie 
(PETRA Studie) beschrieben, (III) empfohlene Ausdauertrainingsintensitätsklassen zu 
Intensitätswerten von hämato-onkologischen Patienten verglichen; und (IV) 
Trainingsadhärenz und ihre Determinanten in verschiedenen Behandlungsphasen, sowie das 
körperliche Aktivitätslevel der Kontrollgruppe in der PETRA Studie beschrieben. Zusätzlich 
wurden in der gemeinsamen Diskussion die Ergebnisse der verschiedenen Untersuchungen in 
den aktuellen Forschungszusammenhang gesetzt. Die Ergebnisse werden dabei helfen, 
Trainingsempfehlungen und körperliche Trainingsprogramme zu verfeinern, und bringen 
wichtige Erkenntnisse für zukünftige Studiengestaltung und Interpretation von Ergebnissen. 
(I) Das erste Manuskript untersucht Daten von 52 Patienten aus der Experimentalgruppe einer 
RCT vor, während und nach allo-HCT. Ergebnisse zeigten, dass zu Beginn unfitte Patienten 
eine signifikant bessere Entwicklung von Muskelkraft und Ausdauer während der 
Intervention hatten, als die initial fitten Patienten. Zum Beispiel verloren die fitten Patienten 
31% ihrer Knie-Extensor-Kraft, während die initial unfitten Patienten nur 1% verloren 
(p=.03). Bezüglich der Ausdauerleistung verloren die fitten Patienten 4%, während sich die 
unfitten Patienten um 13% verbesserten (p<.01). Dieses Ergebnis ist von großer klinischer 
Relevanz, da körperliches Training den eher unfitten Patienten meist nicht empfohlen wird. 
(II) Das zweite Manuskript beschreibt die PETRA Studie. In diese randomisierte, kontrollierte 
Studie werden 256 Patienten vor Beginn einer allo-HCT eingeschlossen. Primärer Endpunkt 
ist das Gesamtüberleben nach zwei Jahren. Sekundäre Endpunkte sind körperliche Fitness, 
Fatigue, Lebensqualität, Schwere der Nebenwirkungen und Biomarker. Zur Erhebung von 
körperlicher Fitness und körperlicher Aktivität werden Gold-Standard-Methoden eingesetzt. 
Die Experimentalgruppe führt ein teilweise supervidiertes, einjähriges körperliches 
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Trainingsprogramm, bestehend aus moderatem Kraft- und Ausdauertraining durch; die 
Kontrollgruppe erhält mit progressiver Muskelentspannung eine vergleichbare Intervention. 
Die PETRA Studie wird eine umfangreiche Datenbasis bereitstellen, um die 
multidimensionalen Effekte von körperlichem Training auf verschiedenste klinische 
Endpunkte hin zu untersuchen. 
(III) Das dritte Manuskript vergleicht erstmals die vom American College of Sports Medicine 
(ACSM) empfohlenen Ausdauertrainings-Intensitätsklassen mit Spiroergometriedaten von 
Krebspatienten (106 Patienten, vor und 180 Tage nach allo-HCT). Die Analyse zeigte, dass 
die Intensitäts-Empfehlungen des ACSM in nahezu fast allen Trainingsintensitäten nicht den 
angestrebten Intensitätsklassen, z.B. von moderater Intensität, entsprechen (p>.05). Die 
Verwendung der ACSM Empfehlungen würde zu einer Über- bzw. Unterschätzung der 
Trainingsintensität bei allogen stammzelltransplantierten Patienten führen. Des Weiteren 
entwickelten wir Tabellen, die zur Empfehlung einer adäquaten Trainingsintensität und zu 
Vergleichen von bereits durchgeführten Trainingsintensitäten in verschiedenen Studien 
herangezogen werden können. Zusätzlich untersuchten wir, ob die häufig verwendete Formel 
220-Lebensalter zur Maximalpulsbestimmung bei Patienten vor und nach allogener 
Stammzelltransplantation verwendet werden kann. Wir fanden heraus, dass sich anhand dieser 
Formel keine adäquaten Trainingsintensitäten ableiten lassen. Mit unseren Ergebnissen ist 
eine bessere Trainingsintensitätsvorgabe für hämatologische Krebspatienten möglich. 
(IV) Das vierte Manuskript untersucht die Trainingsadhärenz und körperliche Aktivität der 
Kontrollgruppe der ersten 153 Patienten der PETRA Studie. Die Adhärenz war mit 66 bis 
77% (89-199 Minuten pro Woche) in allen drei untersuchten Studienphasen (stationär, nach 
Entlassung bis Tag 100 und Tag 100 bis 180) akzeptabel. Wichtigste Determinanten der 
Adhärenz in den verschiedenen Studienphasen waren Fatigue (p=.004), körperliche 
Leistungsfähigkeit (p=.003) und sportliche Aktivität vor der Transplantation (p=.010). Die 
Modelle konnten 16%, 21% bzw. 55% der Varianz erklären. 54% der Patienten in der 
Kontrollgruppe waren nach der Transplantation (Tag 180) sportlich aktiv (89% gaben an, 
regelmäßig spazieren zu gehen). Determinanten für eine Kontamination in der Kontrollgruppe 
waren höhere Muskelkraft (p=.025) und weniger Fatigue (p=.050). Insgesamt konnten durch 
das Modell 29% der Varianz erklärt werden. Die Rekrutierungsrate der ersten 153 Patienten 
der PETRA Studie war sehr gut (73%), so dass wir von einer repräsentativen Stichprobe in 
dieser herausfordernden Population ausgehen können. Die Ergebnisse dieser Untersuchung 
geben wichtige Hinweise zu personalisierten Trainingsvorgaben und für die weitere 
Interpretation von Studiendaten. 
Diese kumulative Thesis stellt grundlegende Informationen hinsichtlich der Frage zur 
Verfügung, wie ein körperliches Trainingsprogramm bei hämato-onkologischen Patienten 
individuell angepasst werden kann. Des Weiteren hilft die Identifikation der Determinanten 
von Trainingsadhärenz und Kontamination zukünftige Trainingsprogramme zu verbessern. 
Darüber hinaus zeigen die Ergebnisse, dass der körperlichen Aktivität der Patienten in der 
Kontrollgruppe mehr Aufmerksamkeit geschenkt werden muss. 
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1 General Introduction 
Cancer is the second most common cause of death in Western countries, including Germany. 
Despite continually improved treatment options, the different treatment modalities are 
associated with a variety of adverse physical and psychosocial symptoms, leading to low 
physical function, increased fatigue levels, anxiety and depression. These distressing 
symptoms affect patients’ quality of life during treatment as well as up to years after 
treatment. In recent years, complementary therapy approaches received more and more 
attention. However, high prevalence of side-effects and complications and severe impact of 
treatment are enormous challenges for implementing exercise interventions in cancer patients. 
Regardless of these difficulties, the rationale for exercise and physical activity interventions in 
cancer patients has been established (1, 2), and results from randomized controlled trials 
(RCTs) provide clear evidence that exercise interventions in cancer patients during and after 
treatment are safe and lead to various beneficial effects (2-7). Due to their multidimensional 
effectiveness, exercise interventions proved to be effective not only on physical performance, 
but also on psychological outcomes, for example cancer- related fatigue (8-10). Overall, there 
is established evidence that exercise has positive effects on quality of life during and after 
treatment (11, 12). 
Courneya and Friedenreich published 2001 an organizational model for examining physical 
exercise across the cancer continuum, entitled Physical Exercise Across the Cancer 
Experience (PEACE). PEACE devides the cancer trajectory in 2 prediagnosis (prescreening 
and screening) and 4 postdiagnosis (pretreatment, treatment, posttreatment and resumption) 
periods, where exercise has a logic role (see figure 1). For exercise intervention studies, the 
last three periods are most important and cover coping, rehabilitation/ palliatation, health 
promotion and survival phase (13). It should be noted that there is evidence from 
epidemiological research that physical activity can reduce the risk of developping some 
cancers e.g. breast and colon cancer (14). For heamatological malignancies, however, no clear 
association could be found (15, 16). 
 
Figure 1: PEACE Framework. An organizational model for examining physical exercise across the cancer 
experience (13). 
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Jones and Alfano recently reviewed the current literature using the PEACE framework in 
order to gain an overview about the current research state in the exercise oncology field and to 
define important reasearch gaps. They concluded that a solid platform exists to launch next 
generation studies, necessary to answer questions concerning optimal dose, individual 
response, and adherence. However, they also raised concerns about problems associated with 
control groups and recruitment (17). These issues/ aspects will be the central subjects of this 
thesis. However, in the field of oncology research, the majority of studies addressed the 
effects of exercise interventions in breast cancer patients, and only few RCTs were performed 
in hematological cancer patients during and after allogeneic stem cell transplantation (allo-
HCT). Therefore, the effectiveness of exercise interventions in allo-HCT patients has not yet 
been fully established. Furthermore, practical implications, regarding exercise guidelines for 
hematological cancer patients are missing.  
General guidelines for exercise prescription in healthy subjects are well defined, including the 
principle components of systematic individualized exercise: mode, intensity, duration, 
frequency and progression (18-21). Intensity is considered as the most important one (19), 
and higher intensity levels are more effective in increasing fitness outcomes (22, 23). As a 
consequence of the growing number of studies in the field of exercise and cancer in the last 
years, a number of exercise recommendations for cancer patients have been published. The 
most influential one is the American College of Sports Medicine (ACSM) roundtable on 
exercise guidelines for cancer survivors by Schmitz et al. (24). This guideline gives a broad 
overview on the current evidence of beneficial effects and exercise recommendations for 
different entities, it gives advice on how to deal with side-effects and points out 
contraindications for exercise. There was consensus that international guidelines for healthy 
people are generally appropriate for cancer survivors, with the additional note that programs 
may need to be adapted depending on the clinical status of the individual patient. Thus, it is 
recommended to be active with moderate activity for 150min per week or vigorous activity 
for 75min per week (24). The Australian guidelines give more specific exercise prescriptions, 
e.g. intensities, but the evidence for the given recommendations remains unclear. The authors 
concluded that there is no evidence concerning the upper and lower thresholds of exercise 
required to achieve benefits and the type of exercise preferred (25). For hematological cancer 
patients undergoing HCT particular resistance exercise is suggested. Furthermore, it is 
recommended to start with lighter intensity and slower progression and to gradually built up 
intensity and duration (26). Overall, the guidelines remain very unspecific, and important 
questions concerning dose (intensity), timing and content of an exercise program remain 
unanswered.  
Buffart et al. summarized and discussed available exercise guidelines for cancer survivors. 
The authors pointed out that problems with program participation and adherence existed. 
They concluded that a ‘one-size-fits-all’ approach did not seem to work in a heterogeneous 
group of cancer patients, and the researchers recommended that prescriptions should be 
individually tailored to the individual characteristics, needs and capabilities of every single 
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patient. Accordingly, the aim should be to develop specific guidelines to describe a given 
exercise intervention with mode/ type, frequency, intensity and duration. In addition, the 
particular phases of cancer trajectory (PEACE framework) should be considered (27).  
In order to enhance exercise prescriptions in hematological cancer patients this thesis 
approaches two issues: In chapter 2 we will address the question whether allo-HCT patients 
with different initial fitness levels prior transplantation respond differently to an exercise 
intervention during and after transplantation. In chapter 4, a comparison of given ACSM 
endurance exercise intensities with intensity classes obtained in hematological cancer patients 
will be presented in order to investigate, if the used exercise intensities for endurance training 
prescription are valid in cancer patients. Both contributions will have an impact on the 
practical implications of exercise prescription in allo-HCT patients.  
Beside the development of more specific guidelines it is of interest, if patients can adhere to 
the given exercise prescription. Adherence is described as the degree to which a patient is able 
to follow the exercise prescription. Only the detailed knowledge of the exercise dose received 
(adherence) allows for correct interpretation of findings and dose-response effects and 
provides information on tolerability and safety. Winters-Stone et al. reviewed reporting of 
adherence to the principles of exercise training, the FITT formula. FITT symbolizes 
frequency, intensity, type and timing of exercise interventions. The researchers concluded that 
the reporting of the FITT criteria regarding adherence is lacking. They stated that it might be 
possible that any null trials were the result of not only poorly designed, but also poorly 
delivered interventions rather than a lack of efficacy. They recommend describing adherence 
based on all FITT components (28). Consequently, a recent review summarized the adherence 
in 20 studies (including 998 patients) following hematopoietic stem cell transplantation. 
Adherence was little reported, with the majority of supervised studies reporting no adherence 
rates at all. Furthermore, the authors pointed out that for translating exercise programs into 
clinical practice it is crucial to include information about attrition. Attrition is described as the 
proportion of participants who failed to complete the research activities or withdrew from 
study. The overall attrition was 18% (range 0-44%), and major reasons for attrition included 
death and change in health status. Since the overall retention rate was high (82%), the authors 
concluded that this reflected the acceptance of exercise and the ability to tailor exercise 
intervention appropriately (29). However, high retention rates might also occur when a 
selective and/or small sample is included, for example, only patients with few side-effects and 
adverse symptoms who are motivated to exercise. Therefore, attention to the amount of 
screened patients and the recruitment rate need to be put in comparison to the total population 
of patients. Only this additional information will ensure a correct interpretation of findings 
and allow for generalisability. 
Moreover, an adoption of exercise behavior in the control group (exercise contamination) is a 
little studied topic in exercise intervention trials. Exercise contamination is only described in 
very few studies and the extent to which it influences the findings is unknown (30-32). 
However, knowledge about determinants of both, adherence and contamination will improve 
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design of future intervention programs and interpretation of study results. Chapter 5 will 
cover the aspects of adherence, contamination, recruitment and retention in the PETRA study. 
The PETRA study is a large RCT during and after allo-HCT and will be described in detail in 
chapter 3. Problems associated with allo-HCT will be described in the next section. 
 
1.1 Allogeneic Stem Cell Transplantation 
Allogeneic stem cell transplantation is an established procedure to treat various hematological 
diseases in high-risk situations, e.g. leukemias, lymphomas and plasma cell disorders. This 
demanding treatment is, however, associated with a large variety of treatment-related side-
effects and complications, leading to physical and psychosocial morbidity. Overall, about 40 
percent of patients with advanced hematological cancers who undergo allo-HCT die from 
complications (33). In 2011, more than 14,000 patients in Europe received an allo-HCT, main 
indications were leukemias (34). In Germany, 2.6% of all new cancer cases in men (and 2.2% 
in women) are attributed to leukemia and 3.3% of all cancer-specific deaths belong to patients 
with this type of cancer. Even though survival rates have substantially improved over the past 
decades, the 5-year survival rate for leukemia is about 50%, and only in very few cases real 
cure can be assumed (35). 
In the past 10 years, the overall number of allo-HCT has doubled (34). The recent 
development of reduced-intensity conditioning-chemotherapy prior allo-HCT resulted in a 
minimization of the toxicity, and has consequently led to a reduced early non-relapse 
mortality. For this reason, more elderly and multimorbid patients, normally not considered for 
allo-HCT, could be treated with transplantation (36, 37). Nonetheless, graft-versus-host 
disease (GvHD), an immune response (autoimmune reaction), induced by donor T-cells 
targeting patient’s tissues, e.g. mucosa, skin and lung remains a major complication after allo-
HCT. Severe GvHD has a poor prognosis with a 5-year-survival of only 25%. Chronic GvHD 
is the major cause of morbidity and transplant-related mortality after allo-HCT (33, 38). 
However, new treatments and improved supportive care lead to improved prognosis and an 
increased life expectancy. Consequently, supportive treatments that improve quality of life 
and re-integration in social life are needed. 
Transplant-related morbidity is evident throughout the whole course of an allo-HCT, from 
pre-transplant conditioning, extending in long-term survivorship after HCT. The occurrence 
of complications and side-effects depends on the treatment period. A large proportion of 
patients present physical deficits already prior to transplantation. In a prospective 
observational study 50% of all 164 patients experienced sacropenia (measured via bio-
impedance analysis). Sacropenia was associated with decreased muscle strength, increased 
fatigue, and lower physical functioning scores (39). A prospective cohort study including 59 
patients showed that in 39% hand grip strength was below 80% of predicted values and the 
submaximal endurance capacity (six-minute walk distance) was reduced in 58% of patients 
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(40). Additionally, another study in 110 patients prior allo-HCT confirmed these findings 
(41). A recent review about muscle dysfunction in cancer patients summarized that muscle 
dysfunction is a common side-effect across all stages of cancer trajectory, and it was 
negatively associated with clinical endpoints, e.g. quality of life, complications and mortality 
(42). Furthermore, cancer cachexia, described as an excessive body weight loss, is known to 
be associated with poor prognosis (43, 44). 
The conditioning chemotherapy in preparation for allo-HCT (in some cases high-dose 
chemotherapy and/ or total body irradiation) suppresses the immune system, leading to a high 
risk of infections (e.g. pneumonia, sepsis) due to a phase of aplasia. This condition requires 
prolonged periods of isolation in single bedrooms in laminar airflow units, until the 
haematological system has recovered. Moreover, mucositis, diarrhoea, nausea, vomiting and 
pain are frequent adverse symptoms in this phase (45, 46).  
As already mentioned, a major complication after allo-HCT is GvHD. Even though, chronic 
GvHD occurs in about 50% of patients, the pathophysiology is poorly understood (47). 
Chronic GvHD has been shown to be associated with a lower physical performance and 
functional capacity (48). In one study in 584 long term survivors, individuals with active 
chronic GvHD (about 50%) had a significant impact on many aspects of overall health status, 
including functional impairments and activity limitation (49). High-dose steroids are the first 
line treatment for GvHD, but they are associated with a variety of adverse side-effects, 
including steroid myopathy. One retrospective study in 70 patients with acute GvHD under 
high-dose steroid treatment could demonstrate that 41% of patients developed a moderate 
steroid myopathy. Furthermore, the myopathy was associated with a moderate to severe 
degree of functional impairment. (50) Moreover, glucocorticosteroids are well known to 
induce muscle wasting (51). In an observational cohort study in 113 allo-HCT patients, the 
total corticosteroid dose was correlated with a decrease of hand-grip and knee-extensor 
strength (52). Furthermore, bed rest studies have shown the negative impact of inactivity on 
muscle performance (53), exacerbating the problem of deconditioning and loss of muscle 
mass given the low activity levels of patients described below. 
Recent literature has shown that patients after HCT are likely to have long-term difficulties 
with physical functioning, problems with fatigue, distress and psychological well-being. 
These quality-of-life and transplanted-related concerns can be present years after 
transplantation (54-56). Furthermore, patients after allo-HCT are at an increased risks of 
cardiovascular events and pulmonary complications (57-59). Some large observational studies 
exist that examined the impact of transplantation years after treatment on different quality of 
life outcomes. Andrykowski et al. recruited survivors through international registries (n=662) 
and assessed a range of patient reported outcomes (PROs) e.g. physical, psychological and 
social functioning via telephone interview. Data were compared with matched healthy 
controls. HCT survivors were at a mean of 7 years after transplantation (1.8 to 22.6 years 
range) and reported an overall poorer health status regarding physical health, physical 
functioning, social functioning, well-being and fatigue (mean effect size for all 24 outcomes 
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was 0.36 standard deviations (SD)) as matched healthy controls. For physical variables, 
largest effect sizes were observed (mean effect size 0.47 SD), whereas the social functioning 
cluster was less affected (mean effect size 0.18 SD). Interestingly, survivors reported more 
psychological and interpersonal growth (60). 
Knowing that a large proportion of side- and late-effects are associated with low physical 
activity levels (61), some studies assessed the physical activity behavior in hematological 
cancer entities. One study in 319 survivors of aggressive non-Hodgkin’s Lymphoma revealed 
that 2-5 years after diagnosis 53% of survivors were less active than the recommended 150 
minutes per week, 20% reported no physical activity at all. Interestingly, individuals who met 
guidelines reported better quality of life. Also, a significant dose-response pattern between 
activity and mental and physical health could be observed (62). This finding was consistent 
with another retrospective study in 156 multiple myeloma patients, where exercise during and 
after treatment was significantly positively associated with various subdomains of quality of 
life (63). Another study in 352 cancer survivors ascertained that not the absolute amount of 
exercise was most important in influencing quality of life, but the change of exercise behavior 
after cancer diagnosis. Survivors who maintained or increased activity levels had a 
significantly higher quality of life (64). In comparison to current guidelines, Valance et al. 
described that 23.7% of 438 non-Hodgkin’s Lymphoma patients met exercise guidelines (150 
min activity per week) off treatment, whereas only 6.5% of this population was sufficiently 
active during treatment (65). However, because these were observational studies, there is no 
causal relationship between health and physical activity. Furthermore, the data were measured 
via self-report and it is well-known that individuals overestimate activity levels when asked 
(66). In conclusion, general activity levels of hematological cancer patients were low, 
requiring effective strategies to enhance activity.  
 
1.2 Exercise in Stem Cell Transplantation 
Emerging evidence indicates positive benefits of exercise intervention in the context of HCT. 
Previous studies demonstrated that exercise might significantly improve physical 
performance, quality of life, symptom control and fatigue in different time points during and 
after HCT (67-72). However, only eight RCTs could be included in the most recent review on 
exercise studies in the HCT setting. Of these trials, only 6 studies included allo-HCT patients, 
and 3 studies examined effects of exercise exclusively in allo-HCT patients (68). As an 
example, Jarden et al. should be mentioned who investigated a supervised multimodal 
exercise program during hospital stay in allo-HCT patients. The exercise program consisted of 
endurance exercise five times per week (15-30 min cycling, >75% HRmax) and resistance 
exercise three times per week (15-20 min). The control group received physiotherapy (up to 
1.5 hours per week). Of 42 included patients, 34 completed the study. Adherence was high 
with 80% of all scheduled cycling sessions and 98% of all resistance training sessions 
attended. Significant group differences could be found at discharge for the primary endpoint 
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maximum oxygen uptake (VO2peak), muscle strength and some side-effects e.g. diarrhoea (73, 
74). In another trial, Mello et al. started their supervised aerobic exercise program (up to 40 
min walking on a treadmill, >70% HRmax, five times per week) after discharge. 18 patients 
after allo-HCT were included, but no adherence data were reported for the 9 exercise group 
participants. Significant effects could be found for different tested muscle groups (75). 
Another large RCT recruited 131 patients (80 autologous HCT and 51 allo-HCT patients). 
The 12-week outpatient supervised intervention started after transplantation (median 79 days 
after HCT) and consisted of 20 min aerobic training (50-80%HRmax) and resistance exercises. 
Adherence was described as attendance (85%). 114 participants completed the study, and 
significant effects were found for physical performance outcomes. It should be noted that this 
study did not included patients with GvHD occurrence (76). The largest RCT in the field of 
allo-HCT so far has been the study by Wiskemann et al. The researchers included 105 patients 
prior allo-HCT. The intervention program started two to three weeks before admission, and 
lasted up to eight weeks after discharge. The exercise program consisted of a mix of 
endurance and resistance exercises and was partly supervised (supervised two times per week 
during inpatient period, weekly phone calls during outpatient setting). The control group 
received the same amount of social contact (visits in hospital and telephone calls) to minimize 
bias regarding social contact. The intervention significantly improved the primary outcome 
fatigue as well as physical performance and distress (77). In addition, a retrospective analysis 
of two-year survival data of this study revealed potential positive effects of exercise on 
overall mortality and non-relapse mortality. However, this was a post-hoc analysis and the 
study was not designed/ powered for this endpoint (78). Consequently, the PETRA study was 
designed. This new study will give a unique opportunity to examine effects of a one-year 
exercise intervention on overall survival, treatment related side-effects and complications 
during and after allo-HCT (see chapter 3 and 5).  
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1.4 Outline  
Results of previous studies in the context of HCT have been heterogeneous due to different 
modalities of exercise interventions as well as differences in treatment and evaluated time 
points. Furthermore, detailed information about adherence and contamination and their 
determinants are lacking. Consequently, there is insufficient evidence regarding the optimal 
exercise prescription, including intensity needed and individual response. The ultimate aim 
should be to develop personalized exercise prescriptions on the basis of current fitness status, 
time during treatment (PEACE framework), needs and preferences. This thesis will contribute 
to the indicated research gaps exploring the following aspects: 
Firstly, physical performance and PRO data of the experimental group of our first RCT will be 
examined further in order to give answer if the initial performance level mediates effects of 
exercise response (Chapter 2). 
Secondly, the design and the rationale of the PETRA study will be described in detail, to give 
background information about the data basis (Chapter 3). 
Thirdly, the widely used ACSM intensity classification for endurance training prescription will 
be compared to values obtained in PETRA patients during cardiopulmonary exercise tests in 
order to give more precise exercise intensity recommendations in hematological cancer patients 
during and after treatment (Chapter 4). 
And finally, recruitment, adherence and contamination of the first 153 patients in the PETRA 
study will be described and determinants for both, adherence and contamination will be 
presented in order to enhance future program design and data interpretation (Chapter 5). 
Chapter 6 will give a short summary of all manuscripts and will discuss the findings in the light 
of the current literature and methodological aspects. This chapter ends with conclusion remarks 
and future perspective. 
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ABSTRACT 
Patients undergoing allogeneic stem cell transplantation (allo-HCT) often experience a substantial loss in physical 
performance. We have recently published the general effectiveness of an exercise intervention in 105 allo-HCT 
patients on physical performance and psychosocial well-being. However, predictor variables for differentiated 
treatment response remained unclear. In order to determine the impact of basic physical performance on treatment 
response we assessed muscle strength and endurance performance at four assessment points before and after allo-
HCT. The exercise group started training 2 weeks before admission and ended 6-8 weeks after discharge. 
Comparing initially fit with unfit classified patients, the fit patients lost 31% of the strength of the knee-extensors, 
whereas the unfit patients lost only 1% (P<0.05). For endurance capacity, fit patients lost 4% of their walking 
capability, whereas unfit patients gained 13% (P<0.05). The individual percent change was statistically different 
at the 0.05 level in all measures of physical performance. Individual training response in allo-HCT patients strongly 
depends on the initial physical performance level. Unfit patients can be trained safely and may benefit more from 
this exercise intervention then fit patients. This result is of major clinical relevance and should encourage 
hematologists to promote exercise even more in impaired/unfit allo-HCT patients. 
Keywords: cancer; physical activity; fitness; endurance; strength; oncology 
 
INTRODUCTION 
Allogeneic stem cell transplantation (allo-HCT) is an 
effective medical treatment option for patients with 
high-risk hematological malignancies such as acute 
leukemia. However, patients may suffer from 
numerous treatment-related side-effects and 
complications e.g. infections, graft-versus-host 
disease (GvHD), and transplant-related mortality 
rate is considerable 1. Prior to allo-HCT, patients' 
physical performance is already affected due to the 
disease itself and prior treatment 2,3. Physical 
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inactivity, resulting from long hospitalization and 
side-effects or complications, leads to an additional 
loss of physical performance. A recent review shows 
that patients after HCT are likely to have long-term 
difficulties with physical functioning, fatigue, 
distress and psychological well-being4. Particularly 
after allo-HCT patients are at high risk because of a 
high prevalence of chronic GvHD, which is 
associated with a lower physical performance and 
functional capacity 5. 
In recent years, several clinical trials have 
contributed to the growing body of evidence about 
the beneficial effects of exercise in cancer patients; 
some general exercise recommendations for cancer 
patients have already been published 6. Our group 
reviewed exercise intervention studies in the context 
of HCT and illustrated that exercise interventions 
can significantly improve physical performance, 
quality of life and fatigue at different time points 
during and after HCT 7. Since this review, 6 new 
RCTs have been published, supporting these 
findings; some studies showed strong effects for 
body composition as well as weaker but promising 
effects for cardiorespiratory fitness, fatigue, muscle 
strength, physical functioning and quality of life 8-13. 
Nevertheless, many questions remain unanswered 
regarding exercise interventions in HCT patients. 
Additional evidence is required to determine the 
optimal exercise recommendation, with respect to 
amount, type, intensity and time-point for 
intervention. Furthermore, the exercise response 
among patients of different baseline fitness levels 
has not been defined and is critical to make 
personalized treatment decisions.   
In healthy populations, the initial level of fitness 
appears to determine the physiological training 
response with greater potential of increase among 
the initially unfit. For example, the HERITAGE 
Family Study investigated intra-individual variation 
in responsiveness to regular exercise training in 
healthy, sedentary individuals and showed that lower 
initial fitness values were associated with greater 
relative changes 14. There are only few studies that 
have investigated the response to an exercise 
program with respect to initial fitness level in 
diseased individuals. A study among cystic fibrosis 
patients showed that a 6-week exercise program led 
to significantly different training responses between 
an initial fit and unfit group, with greater 
improvements in subjects with a lower initial fitness 
level 15. To our knowledge, no information is 
available concerning the benefits of an exercise 
program in relation to initial fitness level among 
HCT-patients. 
Previously, we demonstrated within a RCT that a 
partly self-administered exercise intervention prior, 
during and after allo-HCT is able to improve fatigue, 
physical performance and functioning as well as 
psychological distress and other treatment-related 
side-effects 13. Here, we further define the individual 
training response of the exercising patients with 
respect to initial fitness performing post-hoc 
analysis. To analyze the individual training response 
we classified patients who were randomized to 
exercise (EX) in either a fit or an unfit group and 
measured both endurance capacity and muscle 
strength. 
 
PATIENTS AND METHODS 
Design 
Our study was a prospective, multicenter 
randomized controlled trial (RCT) in allo-HCT 
patients in Germany. Of 112 initially recruited 
patients, 105 started and 80 completed the study. A 
detailed description of the demographics of the 
participants and patient flow is described elsewhere 
13. Briefly, patients were randomized by the 
minimization procedures and stratified by age, 
disease, and sex for each center. Recruitment and 
randomization took place 1-4 weeks before 
admission to hospital. All patients provided written 
informed consent and all procedures were approved 
by the Ethics Committee II of the University of 
Heidelberg/Mannheim and the Physician Board 
Hessen.  
Patients who were randomized to EX started a self-
directed, home-based exercise program 1-4 weeks 
prior to hospital admission. After admission, they 
continued training at the hospital. In this phase, the 
exercise training was supervised 2x/week by an 
exercise therapist. After discharge, patients 
continued with up to 8 weeks of self-directed, home-
based exercise training. At the beginning of the 
intervention, patients were provided with an 
introduction to the exercise protocol and received an 
individualized exercise manual (including DVD). 
During the outpatient period, participants were 
called weekly to review adherence to the 
intervention and identify problems in the EX. The 
intervention consisted of a combination of endurance 
and resistance exercises using stretch bands (3-
5x/week endurance, 2x/week resistance training). A 
single session lasted 20 to 40 minutes. We developed 
a system by which patients can rate their daily 
clinical and psychological status, which we in turn 
used to tailor exercise intensity. Contraindications 
for exercise were platelet counts below 10.000/µl, 
signs of bleeding, hemoglobin level below 8g/dl, 
infections with fever >38oC, severe pain, nausea, or 
dizziness.  
Patients assigned to the control group were informed 
that moderate physical activity is recommended 
during the entire transplantation process, but were 
not given any further exercise recommendations or 
instructions. To avoid socio-psychological bias, 
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patients in the control group received the same 
frequency of social contact (e.g. telephone calls, 
visits in hospital) as the exercise group. 
Outcomes 
All outcomes were measured at four time points 
during the transplantation process. Baseline 
measurements (t0) were obtained 1-4 weeks prior to 
admission, t1 at the day of admission, t2 at the day of 
discharge and t3 6-8 weeks after discharge. 
Maximal voluntary isometric strength (MVIS) was 
measured in Newton [N] by a hand-held-
dynamometer (HHD; company: C.I.T. Technics; 
Netherlands). HHDs have previously been used in 
hematological cancer patients, have proven to be 
reliable and are well-tolerated 16,17. Within 
standardized test positions 18 we assessed seven 
different muscle groups, including knee-extensors, 
knee-flexors, hip-abductors, hip-flexors, elbow-
extensors, elbow-flexors and shoulder-abductors of 
the dominant and non-dominant side. Patients were 
advised to start with low force, and then quickly raise 
the force to their maximum, and to hold it for 3 
seconds. Each measurement was repeated three 
times. Values <10% different from the median were 
excluded. 
Endurance performance was measured by the six-
minute walk test (6MWT) 19,20. The 6MWT is a sub-
maximal performance test which reflects the tasks of 
daily living and has been previously used in 
hematological cancer populations 3,9. Patients were 
advised to walk back and forth down a hallway as 
fast as possible for six minutes. The six-minute walk 
distance (6MWD) was assessed in meters [m]. Heart 
rate was measured before, during and after the test. 
Additionally, the individual perceived exhaustion 
was assessed using the BORG Scale 20. 
Besides physical performance parameters we also 
assessed patients-related outcomes (PROs) as 
follows: Fatigue was assessed with the MFI-20 21, 
quality of life with the EORTC QLQ-30 22 and 
Distress with the NCCN Distress Thermometer 23. 
All questionnaires are widely used in cancer 
populations.  
Statistical analysis 
After tests for normality, χ2 tests, Fisher’s Exact-
Test, and Student’s t-test were used to compare 
group characteristics. ANOVA with repeated 
measurements including the Levene statistic for 
testing homogeneity of variances was used for group 
comparisons. If necessary, the Greenhouse-Geisser 
correction was applied. We calculated the percent 
change from baseline to end of intervention (t0-t3) for 
fit and unfit comparison. For 3- group comparisons 
(EX fit, EX unfit and controls) we conducted an 
ANOVA and defined contrasts. We furthermore 
controlled for age by performing an Analysis of 
Covariance (ANCOVA). The significant level was 
set at α <0.05. All statistical analyses were 
performed using SPSS (German Version 19.0 for 
Windows). 
Patients in EX were classified depending on the 
baseline assessment in either fit or unfit categories, 
specifically for each fitness parameter. For muscle 
strength, patients were classified as fit when they 
reached a minimum of 80% of their age and gender 
specific norm value by Bohannon et al. 18. Patients 
who reached <80% were classified as unfit. 
Due to missing norm values for knee-flexion, hip-
abduction, and shoulder abduction we did not 
include these measurements in our analyses. For 
endurance capacity, the classification procedure was 
the same (≥80% vs <80%) with respect to the 
predicted individual norm value, calculated by the 
gender-specific equations of Enright 24.  
 
 
Figure 1. Study Design (with permission from the journal Blood) 
Manuscript I 
 
 
17 
 
RESULTS 
Demographic and medical characteristics of study 
participants are described in Table 1. More detailed 
information is given elsewhere13. Patient 
characteristics grouped by fit and unfit showed that 
there were no significant differences in sex, age, 
Karnofsky score, disease risk, intensity of 
conditioning, and HLA-match/mismatch. 
Exceptions were the knee extensor strength and 
walking distance where initially unfit patients were 
significantly younger (43.9 ± 14.5 vs 57.5 ± 15.03 
years for knee-extensor and 35.2 ± 14.7 vs 52.8 ± 
12.8 years for 6MWD). Overall, exercise adherence 
was 87% (85%, 83%, and 91% before, during, after 
transplantation, respectively). We observed no 
difference in exercise adherence between EX fit 
(86%) and EX unfit (89%) patients. Furthermore, the 
presence of co-morbidities in the fit, unfit and control 
group was comparable. 27.3% of the EX fit, 17.2% 
of the EX unfit and 30.8% of the controls reported 
cardiologic co-morbidities (e.g. hypertension, 
coronary heart disease). With regard to orthopedic 
co-morbidities 9.1% of the EX fit, 13.8% of the EX 
unfit and 17.1% of the controls reported the presence 
of e.g. a disc prolapse. Psychological disorders were 
present in one patient (2.6%) in the control and three 
patients (10.3%) in the EX unfit group. Finally, one 
patient (3.4%) in the EX unfit and four patients 
(10.3%) in the control group reported the presence of 
diabetes mellitus type II.      
Training response in EX fit and EX unfit   
We observed a stronger benefit of the exercise 
intervention in initially unfit patients compared to fit 
patients for all measured muscle strength groups (all 
P<0.05), with less loss or even gain over the 
transplant period (Table 2). With respect to 
endurance performance, a significantly better 
training response in unfit patients (13.4% vs -3.7%; 
P<0.01) for the 6MWD was observed (Figure 2). 
Furthermore, we detected significant interactions 
(time*group[fit/unfit]) in the age-adjusted 
ANCOVA for changes in knee extensor strength 
(P=0.02) and the 6MWD (P=0.02), illustrating that 
knee strength and endurance development are 
independent with respect to participant age (Table 
2). For hip-flexion, elbow-extension and elbow-
flexion similar effects were observed with p-values 
for the fit/unfit interaction ranging from P= 0.051 to 
0.054. 
 
 
 
 
 
 
 
 
 
 
Table 1. Baseline medical and demographic characteristic  
 All (n= 105) 
Exercise 
(n= 52) 
Control 
(n= 53) 
P- 
value 
Center     
Heidelberg 25 13 12  
Wiesbaden 80 39 41  
Age (mean, range) 
 
48,8 
(18-71) 
 
47,6 
(18-70) 
 
50 
(20-71) 
0.38 
Gender (male/female)    0.10a 
Male (%) 71 32 (45) 39 (55)  
Female (%) 34 21 (62) 13 (38)  
     
Karnofsky score t0 
(median) 90 90 90 0.40
b 
90-100  82 43 39  
80-90  20 7 13  
< 80 3 2 1  
BMI (mean, s.d.) 
 
24.9  
(4.1) 
 
25.1 
(4.3) 
 
24.7 
(3.9) 
0.66 
Diagnosis     
AML 22 12 10  
ALL 14 6 8  
CML 4 2 2  
CLL 4 2 2  
MDS 12 7 5  
Sec. AML 11 6 5  
MPS 13 7 6  
Multiple Myeloma 3 2 1  
Other Lymphomas 20 7 13  
Aplastic Anemia 2 1 1  
Source of stem cell    1.0a 
BM 15 7 8  
Peripheral blood cells  90 45 45  
Donor-recipient 
characteristics 
   0.49a 
HLA-ident (related) 28 13 15  
HLA-matched/ 
unrelated 56 26 30  
HLA-mismatched/ 
unrelated 21 13 8  
Intensity of conditioning    0.82a 
Myeloablative 24 11 13  
Reduced intensity 81 41 40  
Abbreviations:  ALL= acute lymphoblastic leukemia; AML= acute myeloid 
leukemia; BMI, body mass index; CLL= chronic lymphocytic leukemia; 
CML= chronic myeloid leukemia;  HLA, human leukocyte antigen; MDS= 
myelodysplastic syndrome; MPS=myeloproliferative syndrome. 
aFisher exact tes. bWilcoxon test. 
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Table 2. Comparison of muscle strength and endurance performance in initially fit (EX fit) and unfit (EX unfit) of the exercise group 
over study time  
EX fit vs EX unfit Group Comparison 
Variable t0 t1 t2 t3 Change (T0-T3) ANOVA/ANCOVA                 
 mean (s.d.) mean (s.d.) mean (s.d.) mean (s.d.) % P-value  
Knee-extension 
EX fit 
n=11 
326 (53) 268 (73) 231 (69) 224 (73) -31,1 
 
0.03* 
 
Time (P =0.05)* 
Interaction (P =0.02)* 
Group (P =0.47) 
Age (P =0.24) 
EX unfit 
n=28 
257 (93) 293 (149) 234 (104) 235 (92) -1.7% 
 
Hip-flexion 
EX fit 
n=29 
 
 
171 (50) 
 
 
164 (57) 
 
 
153 (59) 
 
 
143 (47) 
 
 
-13.0 
 
 
0.03* 
 
 
Time (P =0.34) 
Interaction (P =0.051) 
Group (P =0.17) 
Age (P =0.44) 
EX unfit 
n=10 
128 (35) 162 (63) 153 (70) 135 (47) 10.3 
 
Elbow-extension 
EX fit 
n=29 
 
 
156 (51) 
 
 
151 (51) 
 
 
135 (56) 
 
 
123 (41) 
 
 
-17.0 
 
 
0.04* 
 
 
Time (P =0.62) 
Interaction (P =0.054) 
Group (P =0.34) 
Age (P =0.37) 
EX unfit 
n=10 
124 (29) 140 (51) 130 (35) 128 (41) 3.4 
 
Elbow-flexion 
EX fit 
n=24 
 
 
204 (65) 
 
 
208 (66) 
 
 
172 (71) 
 
 
159 (43) 
 
 
-18.1 
 
 
0.05* 
 
 
Time (P =0.39) 
Interaction (P =0.052) 
Group (P =0.37) 
Age (P =0.41) 
EX unfit 
n=15 
172 (33) 187 (54) 161 (40) 164 (42) -4.4 
 
Distance 6MWT 
EX fit 
n=28 
 
 
556 (78) 
 
 
563 (82) 
 
 
470 (86) 
 
 
532 (86) 
 
 
-3.7 
 
 
<0.01** 
 
 
Time (P =0.43) 
Interaction (P =0.03)* 
Group (P =0.34) 
Age (P =0.30) 
EX unfit 
n=11 
501 (102) 535 (102) 482 (98) 553 (63) 13.4 
Abbreviations: 6MWT =6-min walk test; ANOVA; analysis of variance; ANCOVA = analysis of covariance. *P=<0.05.**P=<0.01. 
 
 
 
Figure 2. Baseline-stratified changes for different muscle groups and 6-min walk distance in initially 
fit and unfit patients. EX fit = initially fit patients in the exercise group; EX unfit = initially unfit patients 
in the exercise group. 
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Training response compared to controls   
Comparing the percent-changes with the control 
group (EX fit, EX unfit and controls), we found 
significant different group developments for all 
measurements, except for the elbow flexors, 
suggesting a significantly different fitness 
development in the groups. We observed that the 
initially unfit patients developed significantly better 
than the initially fit patients and the controls over 
study time. This was true again for all muscle groups 
and the 6MWD with the exception of elbow flexors. 
There was no difference in the percent-change 
between the fit patients and the CG (see Table 3). 
Figure 3 illustrates the development of knee extensor 
strength and 6MWD for EX fit, EX unfit and controls 
over study time. 
 
Table 3. Comparison of change in muscle strength and endurance 
performance in initially fit (EX fit), unfit (EX unfit) and controls 
over study time 
3- Group comparison (ANOVA) 
EX fit/ EX unfit/ 
controls ANOVA Comparison %-change t0-t3 
Knee-extension 
(n= 11/28/38) 
Group  
(P =0.02)* 
Fit vs controls (P=0.23) 
Unfit vs controls (P =0.03)* 
Fit vs unfit (P <0.01)** 
Hip-flexion 
(n=29/10/38) 
Group  
(P <0.01)** 
Fit vs controls (P =0.31) 
Unfit vs controls (P <0.01)** 
Fit vs unfit (P =0.01)* 
Elbow-extension 
(n=29/10/38) 
Group  
(P =0.02)* 
Fit vs controls (P =0.64) 
Unfit vs controls (P <0.01)** 
Fit vs unfit (P =0.01)** 
Elbow-flexion 
(n=24/15/38) 
Group  
(P =0.09) 
Fit vs controls (P =0.56) 
Unfit vs controls (P =0.07) 
Fit vs unfit (P =0.03)* 
Distance 6MWT 
(n=28/11/38) 
Group  
(P <0.01)** 
Fit vs controls (P =0.13) 
Unfit vs controls (P <0.01)** 
Fit vs unfit (P <0.01)** 
Abbreviations: 6MWT =6-min walk test; ANOVA; analysis of 
variance.*  P=<0.05.** P=<0.01. 
 
Changes in PROs 
We have also investigated whether the different 
development of physical performance parameters in 
the EX fit and EX unfit are related to comparable 
changes in PROs. Results showed that there were no 
significant changes with regard to PROs. 
Nevertheless, we found non-significant changes 
favoring the EX unfit in comparison with the Ex fit 
group with regard to general fatigue (-9.5% vs -
1.4%; n.s.), quality of life (5.0% vs -3.5%; n.s.), 
physical functioning (0.5% vs -8.0%; n.s.) and 
distress (-35.5% vs -28.2%; n.s.). 
 
DISCUSSION 
Our study demonstrates that the individual training 
response in patients undergoing allo-HCT depends 
on the initial performance level. After stratifying by 
baseline fitness levels prior to transplantation, we 
demonstrate that the training response to the partly-
supervised exercise intervention was superior in 
unfit patients compared to fit patients. This implies 
that particularly unfit patients benefited more from 
our program than did fit patients.  
Even if we cannot find a significant relation to PROs 
like fatigue, quality of life and distress, these 
findings are of high clinical relevance because 
exercise is often not recommended for patients with 
poor health status in clinical practice. Physicians as 
well as nurses and exercise-/ physiotherapists tend to 
recommend rest in such situations. In contrast, our 
results indicate that particularly unfit or weak 
patients will benefit from an individually-adapted 
exercise program; thus, for this patient group 
exercising should be strongly recommended. 
As expected, patients were not able to increase 
physical fitness in the context of an intensive 
medical treatment, such as allo-HCT.  Overall, we 
did not observe any gain in muscle strength in the fit 
or unfit group during the overall course of the study. 
Only a small non-significant increase (+10%) in one 
measured muscle group (hip-flexor) was seen in the 
unfit group. Comparable results were reported by 
others10,25 showing that exercising under allo-HCT 
can prevent the loss of physical performance, but 
does not result in increases. Furthermore, the study 
by Defor et al. 26 showed also comparable results 
with regard to the Karnofsky performance score. The 
author found that their 100-day endurance program 
significantly increased Karnofsky performance 
score in the subset of patients who received 
nonmyeloablative treatment indicating a group of 
older and potentially unfit patients. 
With regard to the differential development between 
the fit and unfit groups in our study, one could 
speculate that for the initially fit patients, the 
intensity of the prescribed exercise was too low, 
whereas this intensity might have been the 
appropriate amount for the initially unfit patients. 
There were no differences in adherence between the 
two groups eliminating this as a potential 
explanation. 
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Figure 3: Development of 6-min walk distance (left) and knee-extension muscle strength (right) for initially fit and unfit 
exercising patients and for controls. EX fit = initially fit patients in the exercise group; EX unfit = initially unfit patients in the 
exercise group. 
 
The “inappropriate intensity explanation” for the fit 
patients in the exercise group is supported by the 
observation that there is no differential physical 
performance development between this group and 
the controls. However, the fit group maintained a 
higher performance level during the 
entireintervention period and had therefore a much 
better physical performance outcome than the 
controls. Nevertheless, a better development of 
physical performance in exercising patients should 
be expected when comparing them to a non-
exercising control group, even if they have 
comparable age and gender-specific levels of 
physical fitness prior to the transplantation process. 
Beside the “inappropriate intensity explanation” 
there are several reasons which could explain the 
observation of the similar fitness development 
between the fit exercising and the control patients. It 
is important to consider that our controls were quite 
active due to the general recommendation to stay 
active during the transplant and isolation period. We 
previously published pedometer data and showed 
that there were no significant differences in step 
count between exercising and control patients 13. 
Pedometers and general exercise recommendations 
are known to enhance physical activity/walking time 
in cancer patients 27, which may have also influenced 
our results. Controls also had access to exercise 
equipment (e.g. bicycle ergometers, treadmill, and 
free weights) during the inpatient setting.  Finally, 
controls also received physiotherapy regularly 
during their inpatient stay.  
Our study had several strengths. It was one of the 
largest RCTs in the field of allo-HCT. Due to our 
large sample size, it was possible to perform a sub-
group analysis, investigating training response in 
initially fit and unfit patients. To our knowledge, no 
study has examined whether cancer patients with 
different initial fitness levels respond differently on 
physical exercise training; this question is essential 
and should be addressed when prescribing or 
designing exercise programs in the future. Moreover, 
our intervention was treatment setting overlapping, 
starting 1-4 weeks before admission and ending 6-8 
weeks after discharge, and, our exercise training was 
only partly supervised, and can therefore be easily 
adapted into clinical practice. 
Our study also has some limitations. First, this is a 
retrospective subgroup analysis of an exercise 
intervention trial. Thus, the baseline characteristics 
concerning physical fitness were not randomly 
allocated. Another limitation was that age- and 
gender-specific norm values were not available for 
all measured muscle groups, thus we were unable to 
perform our analyses with all measured muscle 
groups. Nevertheless, based on the observed results, 
we expect comparable developments in the other 
muscle groups. 
The clinical implications of our results emphasize 
the importance of exercise training in initially unfit 
patients during and after allo-HCT. Oncologists and 
exercise therapists should consider that it is possible 
to perform exercise in unfit patients as well as in fit 
patients which might be very important with regard 
to recommended preventive practices in HCT 
patients 28 or new findings in the area of 
hematological reconstitution after HCT 29. Our 
findings also suggest that initially fit patients may 
require more intense exercise recommendations to 
achieve similar benefits as unfit patients. 
Furthermore, it is essential to communicate and 
interpret the potential fitness losses that may occur 
in initially fit patients appropriately. 
Future research should focus on similar 
investigations in other cancer entities and examine 
which subgroups might benefit more from exercise 
during and after cancer treatment as well as try to 
answer the question regarding optimal standards 
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(frequency, intensity and time) of exercise in those 
subgroups. Furthermore, it might be very important 
in future studies to link physical activity behavior 
with the nutritional status of HCT patients 30,31 to 
obtain more insight into the relation between those 
two aspects. With regard to methodological aspects, 
our results also emphasize that baseline fitness levels 
should be considered as a stratifying criterion in 
randomization procedures in order to preclude a 
fitness bias in statistical analyses of clinical exercise 
trials. 
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ABSTRACT 
Background: Allogeneic stem cell transplantation (allo-HCT) is associated with high treatment-related mortality 
and innumerable physical and psychosocial complications and side-effects, such as high fatigue levels, loss of 
physical performance, infections, graft-versus-host disease (GvHD) and distress. This leads to a reduced quality 
of life, not only during and after transplantation, but also in the long term. Exercise interventions have been shown 
to be beneficial in allo-HCT patients. However, to date, no study has focused on long-term effects and survival. 
Previous exercise studies used ‘usual care’ control groups, leaving it unclear to what extent the observed effects 
are based on the physical effects of exercise itself, or rather on psychosocial factors such as personal attention. 
Furthermore, effects of exercise on and severity of GvHD have not been examined so far. We therefore aim to 
investigate the effects and biological mechanisms of exercise on side-effects, complications and survival in allo-
HCT patients during and after transplantation.  
Methods/Design: The PETRA study is a randomized, controlled intervention trial investigating the effects of a 
yearlong partly supervised mixed exercise intervention (endurance and resistance exercises, 3-5 times per week) 
in 256 patients during and after allogeneic stem cell transplantation. Patients in the control group perform 
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progressive muscle relaxation training (Jacobsen method) with the same frequency. Main inclusion criterion is 
planned allo-HCT. Main exclusion criteria are increased fracture risk, no walking capability or severe 
cardiorespiratory problems. Primary endpoint is overall survival after two years; secondary endpoints are non-
relapse mortality, median survival, patient reported outcomes including cancer related fatigue and quality of life, 
physical performance, body composition, haematological/immunological reconstitution, inflammatory 
parameters, severity of complications and side-effects (e.g. GvHD and infections), and cognitive capacity. 
Discussion: The PETRA study will contribute to a better understanding of the physiological and psychological 
effects of exercise training and their biological mechanisms in cancer patients after allo-HCT. The ultimate goal 
is the implementation of optimized intervention programs to reduce side-effects and improve quality of life and 
potentially prognosis after allogeneic stem cell transplantation. 
Trial registration: ClinicalTrials.gov Identifier: NCT01374399 
Keywords: Exercise, stem cell transplantation, prognosis, survival, cancer, mechanisms, fatigue, side-effects, 
mortality, hematological malignancies 
 
BACKGROUND 
Allogeneic stem cell transplantation (allo-HCT) is 
the only curative medical treatment option for 
patients with haematological malignancies in high-
risk situations e.g. acute leukaemia. However, 
patients suffer from numerous treatment related side-
effects and complications, and the transplant-related 
mortality is high [1]. Exercise constitutes a 
potentially promising intervention approach for this 
patient group. Over the last years, several clinical 
trials have contributed to the growing body of 
evidence showing the beneficial effects of exercise 
in cancer patients [2-5], and some general exercise 
recommendations for cancer patients have already 
been published [6] also in the field of allo-HCT [7]. 
Our group has reviewed exercise intervention studies 
in the context of stem cell transplantation and 
illustrated that exercise interventions at different 
time points during and after HCT might significantly 
improve physical performance, quality of life, 
symptom control and fatigue [7]. Since publication 
of this review, 6 new randomized controlled trials 
(RCTs) have been published supporting the findings 
[8-13]. These studies were included in a recent 
review and meta-analysis by Persoon et al. [14] and 
the authors found that exercise significantly 
improved cardiorespiratory fitness, lower extremity 
muscle strength and fatigue and had also a small 
effect on upper extremity muscle strength, quality of 
life (QoL), physical, emotional and cognitive 
function. The researcher concluded that more high-
quality studies were needed [14]. However, it is still 
not possible to give patients clear advice regarding 
the best type, intensity, start and duration of an 
exercise program.  
Prior to allo-HCT, patients’ physical performance is 
already affected due to the disease itself and/or 
previous treatment [15, 16]. Furthermore, emerging 
evidence indicates that cancer patients have 
considerably impaired cardiorespiratory fitness as a 
result of the toxic effects of anticancer therapy or as 
a consequence of the disease (for example cachexia, 
deconditioning, anaemia) [17]. Thus, physical 
activity levels have been described as generally low 
in a group of haematological cancer survivors [18]. 
Furthermore, one study compared the quality of life 
of 662 HCT survivors with age- and sex-matched 
healthy controls and observed poorer general health, 
physical function, well-being, depression, cognitive 
function, and fatigue in HCT survivors [19]. A major 
complication after allo-HCT is graft-versus-host 
disease (GvHD). GvHD is the leading cause of 
morbidity and high transplant-related mortality. It is 
characterized by a reaction of donor T-cells against 
patient tissues e.g. mucosa or skin [1, 20]. Moreover, 
chronic GvHD is associated with a lower physical 
performance and functional capacity [21]. A recent 
review shows that patients after HCT are likely to 
have long-term difficulties with physical 
functioning, problems with fatigue, distress and a 
deteriorated psychological well-being [22]. 
Furthermore, patients after allo-HCT are at increased 
risks of cardiovascular events and pulmonary 
complications [23, 24]. 
Moreover, fatigue is a frequently reported adverse 
side-effect in cancer patients [25]. One study 
described the fatigue experience in allo-HCT 
patients during the first 100 days. In this observation, 
68% reported fatigue at the day of transplantation, 
90% at day 30 and 81% at day 100 after allo-HCT 
[26]. A Cochrane review and an American College 
of Sports Medicine (ACSM) roundtable concluded 
that exercise may be an effective treatment against 
fatigue [2, 6]. Our recently published RCT supports 
these finding by demonstrating positive effects of 
exercise during and after allo-HCT on fatigue [13]. 
Mechanisms underlying the positive effect of 
exercise on fatigue are not fully elucidated, current 
models favor physiological and biological effects, 
for example enhanced physical performance, 
reduced inflammation, and less distress [27, 28]. 
A recent Cochrane review aimed to evaluate the 
effects of aerobic exercise in haematological 
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malignancies. Exercise improved quality of life, 
especially physical functioning, depression and 
fatigue. The authors emphasised that none of the 
included studies investigated effects on survival. 
They concluded that trials with overall survival as 
primary endpoint are needed [29]. So far, the 
evidence regarding a possible influence of exercise 
on survival after cancer diagnosis is limited. A recent 
review by Ballard-Barbash et al. (2012) found 
consistent evidence from 27 observational studies, 
that physical activity is associated with reduced all-
cause, breast-cancer and colon-cancer specific 
mortality, but evidence regarding other cancers is 
currently insufficient [30]. Studies suggest that 
cardio-respiratory fitness may be a robust predictor 
of prognosis in non-small lung cancer patients and 
metastatic breast cancer [17, 31]. Courneya et al. 
(2014) presented for the first time data from a RCT 
in 242 breast cancer patients, and found a non-
significant trend for a better outcome (overall 
survival and disease-free survival) in the exercise 
group [32]. In addition, a small cohort study with 22 
patients showed that patients with low 
cardiorespiratory fitness before allo-HCT had a 
higher risk of mortality after allo-HCT [33], 
furthermore, in a prospective cohort study in allo-
HCT patients, the Karnofsky Performance Score 
(KPS) was an independent predictor of survival, and 
KPS <90% was a predictor of non-relapse mortality 
(NRM) [34]. 
Data from our RCT in allo-HCT patients [13] also 
suggest a potential effect of exercise on survival. We 
observed a significantly reduced two-year total 
mortality (TM) for the experimental group (12% vs. 
28%, p=.034) after inpatient period. The effect was 
controlled for major confounding factors (Gratwohl 
Score, KPS, conditioning regime, gender, and fitness 
prior transplantation). Similar results were observed 
for non-relapse mortality (4% vs. 13%, p=.017) 
when controlled for potential confounders. When we 
included the inpatient period, the risk reductions 
were similar but not significantly different. 
Interestingly, fitness at baseline was protective 
against NRM (p>.001). These results are 
encouraging, however, a major limitation of this 
study is that this was a post-hoc analysis and the 
study was not powered for the primary endpoint 
survival [35]. 
In consequence of the above mentioned findings, we 
currently perform an RCT to investigate the effects 
and biological mechanisms of a partly supervised 
yearlong exercise training on prognosis, 
complications, side-effects and biomarkers in 
patients during and after allo-HCT. To determine the 
specific effect of the exercise intervention itself 
beyond potential psychosocial effects, patients in the 
control group receive a comparable training schedule 
but with muscle relaxation according to the Jacobsen 
method, and the same personal attention as the 
exercise group. 
 
METHODS/DESIGN 
Study design 
The PETRA study (acronym for Physical Exercise 
Training versus Relaxation in Allogeneic stem cell 
transplantation) is a 12-month prospective, 
randomized, controlled clinical intervention trial in 
patients during and after allogeneic stem cell 
transplantation. Patients have to provide written 
informed consent prior to participation in the study. 
After baseline assessments, participants are 
randomized to a mixed type exercise program 
(resistance and endurance exercises) or a relaxation 
program over a period of one year. Both 
interventions are administered partly supervised. 
Endpoints are assessed before admission to hospital 
(baseline, t0), at the day of discharge (t1), day 100 
after transplantation (t2), and day 180, 270 and 365 
post transplantation (t3, t4, t5). Follow-up 
measurement will be 720 days after transplantation. 
[see Figure 1].  
 
Figure 1: CONSORT: Study Flow of the PETRA 
study 
The PETRA study has been approved by the ethic 
committees of the Ethic Committee II of the 
University of Mannheim (number 2009-349N-MA) 
and Heidelberg University (number S-021/2011) and 
is registered at ClinicalTrials.gov (NCT01374399).  
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Objectives 
The primary objective of PETRA is to determine the 
effect of exercise on 2-year overall- survival after 
allo-HCT. 
Secondary objectives are to estimate the effect of 
exercise on 2-year non-relapse mortality, median 
survival, fatigue, quality of life, physical fitness, 
including muscle strength, cardio-respiratory fitness, 
and body composition as well as on cognitive 
function. The effects of exercise on immunologic 
and inflammatory parameters and factors relevant 
for cancer prognosis and GvHD will be investigated 
and compared to the progressive muscle relaxation 
group. Finally, the sustainability of the effects will 
be assessed 720 days after allo-HCT. 
Outcome Measures 
The outcome measures used in the PETRA study are 
summarized in Table 1.  
Primary Outcome 
Two-year overall survival data will be collected 
using medical logs and will be approved by the study 
physician (PD).  
Secondary Outcomes 
Non-relapse mortality and median survival 
We will distinguish between 2-year non-relapse 
mortality (e.g. related to GvHD, sepsis), median 
survival and median disease-free survival. Survival 
data will be collected using medical logs and will be 
approved by the study physician (PD). 
Physical fitness  
Muscle strength is assessed by measuring isometric 
(4 positions) and isokinetic (1 angular velocity) 
maximal muscle capacity with the IsoMed 2000® 
diagnostic module (isokinetic evaluation and 
training machine). The protocol includes testing of 
representative muscle groups for lower (knee 
extensors and flexors, hip flexor and extensor) and 
upper (elbow flexor and extensor) extremity. 
Reliability and validity of isokinetic dynamometer 
machines have been reported in several studies [36-
38]. Additionally, a hand-held-dynamometer (C.I.T. 
Technics) is applied to assess isometrically 6 
different muscle groups within standardized test 
positions (knee-extensors, knee-flexors, hip-
abductors, hip-flexors, elbow-flexors and elbow-
extensors) [39]. Each measurement is repeated 3 
times, values that are <10% different from the 
median will be excluded. Hand-held–dynamometers 
were already applied in hematological cancer 
patients [13, 40, 41]. 
Endurance performance (maximum oxygen uptake, 
VO2peak) is measured by performing a symptom-
limited maximal cardiopulmonary exercise test 
(CPET) with a step protocol (starting at 50 watts 
with steps of 25 watts every 2 minutes) on a bicycle 
ergometer. The criteria of exhaustion is defined as 
achieved estimated maximum heart rate, and 
respiratory exchange ratio >1.1. VO2peak is defined 
as highest 30-second average during the test. Peak 
workload, peak oxygen uptake and oxygen uptake 
and workload at ventilatory threshold will be taken 
for analysis. Cardiorespiratory exercise testing is 
well established in cancer patients and recommenda-
tions for testing procedures as well as safety 
guidelines in clinical trials with cancer populations 
exist [42-44]. Furthermore, the six-minute walk test 
is applied to measure submaximal endurance 
performance. Heat rate and O2-saturation is assessed 
before, during and after the test and the individual 
perceived exhaustion is measured using the RPE-
Scale. [45] For reference values the formula by 
Enright et al. (1998) will be used [46]. The six-
minute walk test was already applied in 
hematological cancer patients [8, 13]. 
Body composition of the participants is estimated 
with bioelectrical impedance analysis (BIA). This 
non-invasive method determines the electrical 
impedance, or opposition to the flow of an electric 
current through body tissues to calculate an estimate 
of total body water, fat-free body mass and body fat 
[47]. BIA gives reliable measurements of body 
composition with minimal intra- and inter-observed 
variability [48]. In addition, body weight and height 
are measured.  
Accelerometer (ActiGraph GT3X) is used to assess 
physical activity behavior. The ActiGraph is a 
triaxial accelerometer, that records motion in 
different planes and provides information about 
intensity, frequency and duration of physical activity 
[49]. Patients will wear the accelerometers during 
hospital stay for the transplantation and at all 
measurement points (except t1) for 10 days at home 
during daytime. Accelerometers were already used 
in HCT patients [50]. 
Quality of life (QoL) 
QoL is assessed with the validated 30-item self-
assessment questionnaire of the European 
Organisation for Research and Treatment of Cancer 
(EORTC QLQ-C30, version 3.0). It includes five 
multi-item functional scales (physical, role, 
emotional, cognitive, and social function), three 
multi-item symptom scales (fatigue, pain, 
nausea/vomiting) and six single items assessing 
further symptoms (dyspnea, insomnia, appetite loss, 
constipation, diarrhea) and financial difficulties [51]. 
In addition, the 29-item high-dose chemotherapy 
(EORTC QLQ-HDC-29) is applied, assessing 
common problems after stem cell transplantation, 
e.g. gastro-intestinal side-effects and worry/anxiety 
[52]. Scores will be derived according to the EORTC 
scoring manual. Reference values are available from 
the EORTC reference manual, a review, including 
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2,800 patients before and after HCT [53] and from a 
sample of the general German population stratified 
by gender and age [54]. Furthermore, evidence-
based guidelines for the interpretation of the clinical 
relevance of changes in the different EORTC QLQ-
C30 subscales were recently published [55], 
categorizing differences between scores in trivial, 
small, medium or large effect sizes.  
Fatigue 
Fatigue will be assessed with the Multidimensional 
Fatigue Inventory (MFI) which is a 20-item, 
multidimensional self-assessment questionnaire that 
has been validated for a German-speaking 
population [56]. It covers five different dimensions 
of fatigue (general fatigue, physical fatigue, reduced 
activity, reduced motivation and mental fatigue). 
Scores are derived by summing the answers (five-
stage scale) of the appropriate items.  
 
Table 1 Assessments and instruments used in the PETRA study 
Outcomes  Instrument t0 t1 t2 t3 t4 t5 t6 
Primary endpoint 
Overall 2-year survival Medical log (ongoing assessment)  
Secondary endpoints 
2-year non-relapse mortality, 
median (disease-free) survival 
Medical log (ongoing assessment)  
Quality of life EORTC QLQ30 / HDC-29 module X X X X X X X 
Fatigue Multidimensional Fatigue Inventory (MFI) X X X X X X X 
Muscle strength Isometric and isokinetic strength of 
representative muscle groups for upper and 
lower extremity measured at the IsoMed2000® 
X   X  X X 
Hand-Held-Dynamometer (isometric) X X X X X X X 
Cardiorespiratory fitness CPET (VO2peak) X   X  X X 
 6-Minute Walk Test X X X X X X X 
Body composition bioelectrical impedance analysis, weight, height X X X X X X X 
Physical Activity Accelerometry X  X X X X X 
Depression CES-D X X X X X X X 
Distress NCCN-Distress X X X X X X X 
Locus of control KKG (German) X X X X X X X 
Cognitive function Trail-making-test X X X X X X X 
Common side-effects VAS, every week, later every 3 weeks  
Biomarker Various methods (ELISA) X X X X X X X 
Oxidative stress marker Analysed in urine samples X X X X X X X 
Others 
Socio-demographic factors Recording of date of birth, education, 
occupation, familial situation, smoking, alcohol 
consumption 
X     X X 
Medical history Recording of pre-existing diseases, therapies X       
Treatment data Conditioning, complications  X      
Karnofsky Performance Score Physician rating X X X X X X X 
Medication 
(immunosuppression, 
corticosteroids, analgesics) 
Recorded at each visit/phone call on a 
medication log form 
X X X X X X X 
Physical activity history Physical activity in adolescence, pre-diagnosis, 
during, and after intervention is recorded, 
including walking, cycling, and sports activities 
X   X  X X 
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Reference values of the MFI scores are available 
from a representative sample of the German 
population including 2,037 subjects [57]. The use of 
the MFI is recommended in cancer patients [58]. 
Distress 
Distress will be assessed with the Distress-
Thermometer, developed from the National 
Comprehensive Cancer Network (NCCN) as a 
screening tool [59, 60]. The Distress-Thermometer 
has already been validated in stem cell 
transplantation patients [61]. 
Depression 
Depressive symptoms are assessed with the 20-item 
Center for Epidemiological Studies Depression 
Scale (CES-D). The CES-D scale is a widely used 
validated self-report instrument to measure current 
depressive symptomatology and to identify possible 
cases of depressive disorders, both in the general 
population and in patients with cancer [62]. 
Locus of control 
Locus of control is measured by a validated German 
21-item questionnaire Assessment of health and 
sickness locus of control (KKG). It comprises 3 
subscales, assessing internal, social external and 
fatalistic external locus of control. [63] The 
questionnaire is based on the Multidimensional 
Health Locus of Control Scale (MHLC) [64]. 
Cognitive function 
The cognitive function (concentration, cognitive 
flexibility) is estimated using the trail-making-test. 
This is a standardized, reliable and valid measure 
used in neuropsychological diagnostics [65, 66]. The 
test measures the time needed by the participant to 
connect numbers and letters spread over a sheet of 
paper in a logical sequence. 
Biomarkers 
Serum and PBMCs are derived from whole 
peripheral blood samples, processed within 4 hours 
after taking the blood sample and stored at -80°C or 
cryopreserved in liquid nitrogen (PBMCs) for 
analyses of biomarkers. Urine samples are collected 
for analyses of biomarkers of oxidative stress, i.e. 
urinary F2-isoprostane and 8-oxo-dG measured by 
chromatography-based methodology. Blood 
samples are collected for analyses of biomarkers of 
GvHD, i.e. inflammatory (e.g. IL-1, IL-4, IL-10, 
TNF-α) and endothelial parameters (e.g. 
angiopoetin-2, thrombomodulin (sTM)) measured 
by ELISA. 
Side-effects of cancer treatment 
Severity and duration of GvHD will be recorded by 
attending physicians every week according to the 
classification by Thomas et al. [67]. Furthermore, 
during allo-HCT and up to day 100 after, common 
side effects like nausea, diarrhea, appetite loss, pain, 
fatigue, concentration difficulties and anxiety are 
assessed weekly during phone calls using a visual 
analogue scale. After day 100 until the end of 
intervention (day 365 after) patients are questioned 
on these parameters during every phone call 
(depending on clinical status every 2-4 weeks). 
Infections are documented via medical chart review. 
Safety issues 
Potential adverse events (AEs) and serious adverse 
events (SAEs) causally related to the intervention or 
assessment procedure will be recorded. Patients are 
informed about contraindications for exercise 
sessions (thrombopenia, bleeding, infections 
including fever, dizziness, strong nausea/ vomiting, 
and strong pain) and advised to stop exercising when 
they feel that symptoms get stronger. 
Sample size 
Sample size was chosen to achieve adequate 
statistical power (1-β = 0.8) for detecting a 
difference between the exercise and relaxation group 
with respect to two-year overall survival (primary 
outcome). The calculation is based on the two-year 
overall survival rates of our previous RCT (0.66 in 
the exercise group vs 0.49 in the control group) [35]. 
Accordingly, 128 participants per group (total 
number = 256) are needed to achieve adequate power 
to detect a significant (two-tailed α = 0.05) 
difference from Kaplan-Meier estimates tested for 
equality by log-rank tests.  
Participants and setting 
All patients, scheduled for an allo-HCT at the 
Heidelberg University Clinic are invited to 
participate in the PETRA study. Inclusion criteria are 
age ≥18 years and the ability to understand and 
follow the study protocol. Exclusion criteria 
comprise contra-indications for progressive exercise 
training, i.e. inability to walk or stand, instable bone 
lesions, severe neurological deficiencies, severe 
cardiac or cardiovascular diseases and severe 
pulmonary global insufficiency.  
Recruitment and randomization 
All eligible patients scheduled for allo-HCT at the 
University Hospital in Heidelberg are briefly 
informed about the PETRA study during the 
preparation visit (about 2-3 weeks before admission 
for allo-HCT) by case-management. If interested, 
patients are then informed in detail by the PETRA 
study coordinator. Upon written informed consent, 
the patient is included in the trial and scheduled for 
baseline assessment (t0), which should be within 14 
days prior to start of conditioning for allo-HCT. 
After completion of the baseline assessments, the 
participant is randomly allocated to one of the two 
intervention groups. Allocation is done by the 
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minimization method [68] stratified by disease, age 
(< 40 / ≥ 40 years of age), gender, remission state 
(CR/ no CR), and intensity of conditioning (full/ 
doses reduced). Stratification is used in the 
randomization process, as we anticipate these 
variables to have major influence on the outcome.  
Interventions 
The training starts at the same day as the 
conditioning treatment. Both intervention programs 
are performed 3-5 times per week for 12 months. 
During the first phase (hospital stay for allo-HCT) 
participants perform the program 3 times under 
supervision and guidance of an experienced 
therapist, 2 times self-directed. During the second 
phase (after discharge), patients perform both 
interventions self-directed at home. Until assessment 
on day 100 weekly phone calls in both groups will 
allow for adaptation of the program and enhance 
motivation/ adherence, 3 training sessions per week 
are recommended. After day 100 assessment, phone 
calls will take place every 2-3 weeks.  
Exercise Intervention 
All patients receive an exercise manual with 
background information (including 
contraindications for training, motivation), 
instructions for tailoring the training intensity 
(depending on clinical status), descriptions for 
different resistance exercises for the whole body and 
endurance exercises. Patients receive stretch bands 
and free weights for resistance exercises, for 
endurance exercises patients have access to a 
stationary bicycle (patient room) and a treadmill 
(hallway) during the inpatient period. We developed 
a self-rating instrument which helps patients to find 
the appropriate exercise intensity (including RPE 
scale) [13]. The exercise intervention complies with 
the ACSM exercise guidelines for cancer survivors 
and healthy adults and is progressed on an individual 
basis [6, 69]. A complete resistance training session 
includes 6 to 10 exercises for major upper and lower 
muscle groups and is recommended 2-3 times per 
week. Endurance training comprises bicycling or 
walking/jogging 3 times per week. Patients are 
encouraged to increase exercise intensity when they 
reach 3 sets of 12 repetitions for the resistance 
exercises or when they feel less exhausted using the 
RPE-scale (target 12-14 for endurance exercise, 14-
16 for resistance exercise) [70]. The exercise 
program is performed on a very individual basis and 
includes also some psychological aspects e.g. 
motivation, goal setting, dealing with barriers, and 
regular feedback on physical performance data is 
given to promote adherence. [71] Adherence to FITT 
components (frequency, intensity, type, timing) will 
be described [72] to ensure correct interpretation of 
the findings. Furthermore, it is possible to perform 
the training in an appropriate sport/ exercise facility 
close to patients’ homes. Within the scope of the 
PETRA study we will also develop a network called 
‘OnkoActive’, which will enable referral to 
specialized exercise facilities. Furthermore, within 
‘OnkoActive’ an internet-based training platform 
will be developed to support the home-based 
intervention. 
Relaxation Intervention 
The progressive muscle relaxation method according 
to Jacobsen does not include any aerobic or muscle 
strengthening components [73]. Patients receive a 
manual with background information, an audio CD 
with 2 different versions (long/ short version) and a 
portable CD player. Patients in the control group will 
receive the standard physiotherapy program and will 
also have access to a bicycle ergometer and treadmill 
during the inpatient period.  
Data analysis 
The main intervention effect will be assessed on the 
basis of a Cox-regression analysis between 
exercisers and controls (relaxation group) as defined 
at randomization, regardless of exercise adherence, 
i.e. according to the intent-to-treat principle. 
The differences in secondary endpoints between 
groups will be assessed using mixed models, which 
accounts for repeated observations on the same 
subjects over time. This method provides a more 
efficient estimate of the intervention effect in 
pretest-post-test trials than traditional methods [74]. 
Mixed models will also be used for testing to which 
extent differences between the treatment groups 
depend on training adherence, changes in muscle 
strength, cardiorespiratory fitness, and body 
composition. Normality assumptions will be 
checked and, if deviation from normality is detected 
the data will be transformed accordingly.  
In addition, change in physical activity behavior post 
intervention will be monitored on an explorative 
basis. 
 
DISCUSSION  
Treating hematological malignant diseases with allo-
HCT is highly demanding for patients who 
experience numerous side-effects and face a very 
high risk of severe treatment related complications, 
such as GvHD and severe infections, both in the 
short and long-term. In general, survival rates after 
allo-HCT are relatively low. 
Recently, our group demonstrated that there may be 
a positive effect of exercise on survival after allo-
HCT. In our first RCT we observed a significant 
reduced total mortality for the experimental group 
(12% vs. 28%, p=.034) and for NRM (4% vs. 13%, 
p=.017). Furthermore, we observed that physical 
fitness prior transplantation was highly protective 
against NRM [35]. The cohort study by Wood et al. 
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also suggests an association between fitness level 
prior transplantation and risk of mortality [33], but a 
small sample size of 22 patients and no use of 
multivariate models hamper the interpretation of 
these results. Against this background we designed 
the PETRA study. PETRA will add to current 
knowledge on exercise in allo-HCT patients with 
respect to several aspects: (1) Effect of yearlong 
exercise intervention on prognosis; (2) exercise 
effect on side-effects and complications, e.g. 
physical performance, QoL, fatigue; (3) exercise 
effect on GvHD and hematological/immunological 
reconstitution; and (4) sustainability and long-term 
effects of exercise intervention. 
Given the indication of reducing mortality in cancer 
survivors by an appropriate physical active lifestyle, 
the question about possible mechanisms occurs. 
Some evidence suggests several potential 
mechanisms underlying [30]. One discussed 
mechanism is inflammation [75]. Several trials 
reported that exercise can reduce C-reactive protein 
(CRP), which is a marker of chronic inflammation 
[76-78] and change Interleukin-6 (IL-6) levels. IL-6 
produced by muscle fibers during and after exercise 
stimulates the circulation of anti-inflammatory 
cytokines, such as IL-1ra and IL-10 and inhibits the 
production of tumor necrosis factor alpha (TNF-α) 
[79]. In a prospective cohort study in breast cancer 
patients, elevated CRP and serum amyloid A were 
associated with reduced overall survival [80]. 
Furthermore, when exercise potentially can 
influence parts of the immune system, the question 
arises, if a GvHD reaction in allo-HCT patients can 
also be influenced by exercise. To our knowledge, 
no intervention study in humans investigated a 
possible association between exercise and severity of 
the major side-effect GVHD. New results from mice 
experiments suggest that physical exercise can have 
a positive impact on GvHD. The researchers showed 
that endurance training (5 times per week) in mice 
was beneficial with regard to overall survival and 
also alters GvHD symptom severity. Furthermore, 
the authors revealed possible pathways for altering 
GvHD by demonstrating that exercising mice had 
lower levels of anti-inflammatory cytokines (IL-4 
and TNF-α) [81]. Based on these findings, we aim to 
investigate whether exercise is able to alter GvHD 
severity in human adults. We are further interested 
to elucidate other possible exercise pathways 
altering GvHD by investigation of endothelial 
markers. Markers of interest are blood biomarkers of 
inflammation and TNF-α as well as endothelial 
markers and hepatocyte growth factor [82-85]. 
Natural killer cells (NK-cells) have also been shown 
to modulate acute GvHD, infections and recurrence 
[86, 87]. The positive effect of exercise on NK-cell 
activity in cancer patients could already be shown in 
studies [88], and a review about NK-cells and 
exercise suggests exercise as an adjunct therapy to 
promote expansion of NK-cell subsets [89]. 
Interestingly, one RCT in allo-HCT patients could 
already observe a positive effect of exercise during 
transplantation process on lymphocyte count [90]. 
Additionally, restoring the function of the entire 
haematological system after allo-HCT is an 
important prognostic indicator [91, 92]. Therefore, 
we focus also on exercise effects on haematological 
recovery after allo-HCT. A potential positive effect 
on the haematological system e.g. lymphocytes, 
haemoglobin could already be shown [8, 90, 93]. 
A central secondary endpoint is cancer-related 
fatigue. Fatigue is described as the most distressing 
side effect in cancer treatment, however, the 
pathophysiology of fatigue and the possible positive 
effect of exercise on its prevention/therapy are not 
well understood [94]. Therefore, our trial enables 
investigation of the effects of exercise on 
immunologic parameters as well as on biomarkers of 
inflammation and oxidative stress as possible 
mediators of fatigue [95, 96]. However, not only 
fatigue is a common side-effect. As a consequence 
of longer periods of drug intake, e.g. immune 
suppression and antibiotics, patients often suffer 
from nausea, diarrhea and further complaints. Recent 
studies indicated a better symptom control in 
exercising patients [97]. 
Our decision of choosing an intervention period of 
one year was based on the consideration that the 
recovery period after allo-HCT can take months to 
years. However, even years after allo-HCT patients 
have an increased risk to develop co-morbid 
conditions, e.g. metabolic or cardiovascular diseases 
[22]. On one hand, emerging research evidence 
indicates that these life style diseases are associated 
with physical inactivity. On the other hand, studies 
show that hematological cancer survivors are less 
likely to be physically active. Moreover, changing 
exercise behavior requires longer, individually 
adapted interventions. To enhance motivation and 
adherence, the PETRA study uses goal setting 
methods, and individual barriers are discussed 
during regular phone calls. These components have 
been shown to improve adherence [71]. 
Furthermore, PETRA helps patients to integrate in 
an exercise facility close to their home or give them 
the possibility to perform an internet-based training 
program. All these efforts may help patients to 
change the physical activity behavior in the long 
term. Finally, if during or at the end of the exercise 
intervention beneficial effects are detected, it is of 
interest whether those benefits sustain over a longer 
period of time.  
Strengths of the PETRA study are the rigorous study 
design with a large sample size, adequately powered 
for the primary endpoint survival, and a broad range 
of assessments, including gold-standard methods for 
physical fitness and physical activity. Therefore, 
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PETRA provides a unique opportunity to examine 
the interaction of exercise/ physical activity on the 
haematological system and GvHD reaction. A 
further strength is the choice of the control group 
(relaxation training). Previous exercise RCT used 
typically usual care as comparison groups. Thus, it is 
unclear to what extent the observed effects are based 
on the physical exercise effect itself, or rather on 
psycho-social factors related to social support or 
attention by the trainer. This factor is particularly 
important when psychosocial outcomes are 
measured.  
Summary  
Previous studies in allo-HCT patients established 
first evidence about beneficial effects of exercise 
interventions on physical and psychosocial 
outcomes. However, the focus changed to more 
clinically relevant endpoints, e.g. prognosis. To our 
knowledge, no study has yet investigated a possible 
effect of exercise on overall survival after allo-HCT. 
Furthermore, there is a need for a better 
understanding of the physiological and 
psychological effects of exercise and their biological 
mechanisms in patients during and after allo-HCT. 
The PETRA study will provide a comprehensive 
picture of the potential effects of exercise during and 
after allo-HCT on overall survival, reducing side-
effects and complications, and improving quality of 
life. We anticipate that our study will help to refine 
exercise guidelines for allo-HCTpatients. 
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ABSTRACT 
Objective: Exercise intervention studies during and after cancer treatment show beneficial effects for various 
physical and psychosocial outcomes. Current exercise intensity guidelines for cancer patients are rather general 
and have been adapted from ACSM recommendations for healthy individuals. Intensive cancer treatment regimens 
such as allogeneic stem cell transplantation (allo-HCT) may change the cardiovascular response to acute exercise. 
Therefore, we evaluated the relationships between %VO2 reserve (%VO2R, reference) and %HRR, %HRmax, 
and %VO2max and compared calculated intensities to given intensities by ACSM. Methods: Measurements prior 
to and 180 days after allo-HCT from a randomized, controlled trial were used. Only patients who reached maximal 
effort and at least two exercise stages in our maximal incremental cycling test were included. Prior to allo-HCT, 
106 patients were included, and 180 days after treatment, 49 patients met our inclusion criteria. Individual 
regression lines were calculated with VO2R as the reference. Calculated exercise intensities for endurance training 
prescription were compared to ACSM values. Results: Prior to allo-HCT, %HRR values of patients were 
significantly lower than ACSM values, and %HRmax and %VO2max values were significantly higher (except 
90% HRmax, which was significantly lower, all p<.01). 180 days after allo-HCT, values for %HRR were not 
significantly different to ACSM values (except 90%, which was significantly lower, p=.01), whereas %HRmax 
and %VO2max were significantly higher (all p<.05). Furthermore, regression models revealed no influence of 
beta-blockers on calculated intensities. Conclusions: ACSM’s exercise intensity recommendations for endurance 
training may not be applicable for cancer patients during and 180 days after allo-HCT because they may not meet 
the targeted intensity class, with the exception of %HRR 180 days after allo-HCT. 
Keywords: exercise, cancer, intensity, transplantation, oncology
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INTRODUCTION 
Exercise intervention studies in hematological 
cancer patients during and after therapy have 
demonstrated safety and beneficial effects on 
physiological and psychological outcomes (26, 36, 
37). The accumulating evidence about beneficial 
effects of exercise in cancer survivors has led the 
American College of Sports Medicine (ACSM) to 
develop exercise guidelines for cancer survivors; it 
is recommended to perform aerobic exercise for 150 
minutes per week with moderate, or 75 minutes per 
week with vigorous intensity (27). These guidelines 
were adapted from existing recommendations for 
exercise from the ACSM for healthy individuals (13) 
noting that exercise programs in cancer survivors 
may need to be modified considering health status 
and treatment received. (27) Thus, the guidelines do 
not provide exact training intensities as a result of a 
lack of information in previous studies (4). However, 
prescription of adequate intensity is crucial for both 
adequate training stimulus and control for exercise 
related risks; further, appropriate prescriptions are 
essential in terms of exploring dose-response effects 
(35). ACSM guidelines for healthy individuals 
recommend intensities for moderate endurance 
training of 40-59% heart rate reserve (HRR), 64-
76% maximal heart rate (HRmax) or 46-63% maximal 
oxygen consumption (VO2max) (13). Most exercise 
studies in hematological cancer patients that used 
exercise intensity prescriptions relied on commonly 
used equations for age-predicted HRmax estimates 
(e.g. 220-age in years) (17, 19, 34). 
However, the relationship between HR and VO2 
during exercise may be different in hematological 
cancer patients and might change over time. 
Allogeneic stem cell transplantation (allo-HCT) 
used in hematological cancers is a very intense 
treatment regimen which is comprised of high-dose 
chemotherapy, intake of immunosuppressants and 
high-dose corticosteroids, and in some cases, total 
body irradiation (7). A substantial amount of 
evidence has shown that cancer patients have a 
marked reduction in cardiorespiratory fitness as a 
result of the toxic effects of anti-cancer therapy and 
physical inactivity during and after treatment (18, 
20). The causes are often multifactorial and involve 
pulmonary limitations after chest radiation, cardiac 
limitations after antracycline-containing 
chemotherapy or mediastinal radiation, low 
hemoglobin levels, or alterations in the skeletal 
muscle oxidative capacity (12, 20). Furthermore, 
even before transplantation, patients’ physical 
performance is reduced (33) and a long period of 
drug intake after allo-HCT (e.g. immuno-
suppressants and corticosteroids) is known to cause 
muscle wasting (21), which also may influence the 
addressed relationship. 
Therefore, our aim was to investigate whether the 
ACSM intensity classification for healthy people and 
the application of age-predicted HRmax estimates are 
appropriate for endurance training prescriptions in 
hematological cancer patients prior to and after allo-
HCT, and to examine if the relationship between 
VO2 and HR changes after therapy. Thereby, age, 
gender, BMI, hemoglobin level and beta-blocker 
intake were considered as covariates. 
 
METHODS 
Design 
Data were obtained from the PETRA study. The 
PETRA study is a randomized controlled ongoing 
one-year exercise intervention study in allo-HCT 
patients. Patients assigned to the experimental group 
(EG) received an endurance and resistance training 
program, whereas patients in the control group (CG) 
received a relaxation program. Patients conducted 
maximal cardiopulmonary exercise tests (CPET) at 
three time points. In the present analysis we included 
all patients who performed at least one maximal 
CPET at two different assessment time points, prior 
to allo-HCT and/or 180 days after, and completed a 
minimum of 2 exercise stages of the maximal CPET. 
The assessment time points were selected because 
they include the period of intensive treatment and 
appear to be a common time point for starting 
exercise in the context of a rehabilitation program. 
The study has been approved by the Ethics 
Committees of the University of Mannheim (number 
2009-349N-MA) and Heidelberg (number S-
021/2011) and is registered at ClinicalTrials.gov 
(NCT01374399). Written informed consent was 
obtained from each participant prior to first 
assessment. 
Subjects 
A total of 110 hematological cancer patients were 
included in the analysis. Exclusion criteria were 
premature exercise cessation due to medical reasons, 
or lack of maximal effort (exhaustion criteria: RER 
>1.1 or HR >85 % of age-predicted maximum (16, 
25)). The most frequent disease was acute myeloid 
leukemia (n=28), followed by chronic myeloid 
leukemia (n=22), lymphoma (n=18), multiple 
myeloma (n=12), acute lymphatic leukemia (n=7), 
chronic lymphatic leukemia (n=6), and others 
(n=13). 43% (n=46) patients were in complete 
remission prior allo-HCT. Subjects’ detailed 
characteristics are presented in table 1. Due to the 
following reasons we could not collect data in 61 
patients for the second measurement point (180 days 
after allo-HCT): assessment point was not yet 
reached (n=21), patients died (n=16), drop-outs 
(n=6), medical reasons (n=8), and others (n=10). For 
four patients included in the second measurement 
point, we had no data for the first time point. At the 
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second measurement point 27 patients (55%) were in 
the EG.  
Data collection 
All maximal CPETs were performed on an 
electronically braked cycle ergometer (Ergoselect 
100, Ergoline, Bitz, Germany) and were monitored 
by a physician. The test protocol was a graded 
procedure of two-minute stages starting at 50 W and 
increasing by 25 W until voluntary exhaustion or 
medical reasons for premature exercise cessation. 
Cadence was kept constant between 60 and 70 rpm. 
A 12-lead ECG was recorded continuously and 
blood pressure was measured every two minutes. 
Gas exchange measurements were performed 
continuously using a breath-by-breath system 
(Ergostik, Geratherm Respiratory, Bad Kissingen, 
Germany). The metabolic device was calibrated 
before each test according to the instructions 
provided by the manufacturer. Gas exchange data 
and HR were stationary time averaged over 30 s. 
VO2max and HRmax were considered the highest 30 s 
average value during or immediately post exercise. 
Maximal respiratory exchange ratio (RERmax) was 
considered the highest 30 s average value during 
exercise.  
 
Data extraction and statistical analysis 
HR and VO2 were assessed at the end of each 
exercise stage and at maximum. Ventilatory 
threshold (VT) was determined according to the V-
Slope method (2). To calculate HRR and VO2R, 
resting data were obtained from the resting period 
prior to the start of the exercise test in a sitting 
position on the cycle ergometer (VO2) and in laying 
position during resting ECG (HR). HRR and VO2R 
were calculated by subtracting the resting value from 
the maximum value. Values of each exercise stage 
were expressed in %VO2max, %HRmax, %VO2R, 
%HRR, % of maximal power output (%Pmax), and 
%VT (the latter two are not part of the ACSM 
recommendations, but are commonly used for 
training prescriptions (6, 8)). After testing for 
normality, five linear regression analyses were 
calculated for each subject and test. We used 
%VO2R as the independent variable (reference to 
define exercise classes), and %VO2max, %HRmax, 
%HRR, %Pmax, or %VT as dependent variables, 
respectively. We selected VO2R as the reference 
because reserve values are superior to maximal 
values and VO2R represents the individual 
performance capacity (13). . The resulting individual 
regression equations were used to calculate the 
%VO2max, %HRmax, %HRR, %Pmax, and %VT values 
that correspond to 30, 40, 60, and 90 % VO2R, 
corresponding to the lower limit of light, moderate, 
vigorous , and near maximal intensity by ACSM. 
Additionally, we estimated HRmax and HRR with the 
equation 220-age (in years), as previously used in 
exercise studies. One-sample t-tests were used to 
compare the resulting values to the ACSM’s 
expected values. To compare differences between 
the two time points paired t-tests were used. 
Furthermore, multiple regression models were 
applied to determine influence of beta-blocker intake 
(BB), age, gender, BMI, and hemoglobin level (Hb) 
on measured and calculated values. The probability 
of making a Type I error was set at P < 0.05. 
Statistical analyses were performed using SAS 9.3. 
 
RESULTS 
Comparison to ACSM values 
Table 2a displays the results prior to transplantation. 
All %HRR, %HRmax, and %VO2max means, 
corresponding to 30, 40, 60, and 90 %VO2R, were 
significantly different from the ACSM’s 
recommended values. Whereas the %HRR values of 
the patients were significantly lower than ACSM 
recommendations, %HRmax and %VO2max values 
were significantly higher (except 90%HRmax). 
Additionally, VT was located at 40% of VO2R. 
Figure 1 shows the regression lines for our patients 
in comparison to the ACSM values. 
Table 2b displays the results 180 days after 
transplantation. Here, similar results for %HRmax and 
%VO2max were observed as for the measurement 
time point prior to transplantation. For %HRR, there 
was no significant difference between ACSM 
recommendations and patients’ values (except 
90%HRR, where patients’ values were still 
significantly lower). Group assignment (exercise vs. 
relaxation control) had no effect on regression 
lines180 days after transplantation, and paired t-tests 
showed no significant changes in%HRR, %HRmax, 
and %VO2max values over time (all P > 0.05). 
TABLE 1. Subject characteristics before and 180 d after allo-
HCT 
 Before allo-HCT (n=106) 
180 d after allo-HCT 
(n=49) 
Age (yr) 52 ± 11 54 ± 11 
Male 73 (69%) 36 (73%) 
Female 33 (31%) 13 (27%) 
Height (m) 1.73 ± 0.08 1.75 ± 0.10 
Weight (kg) 80.46 ± 16.44 77.50 ± 14.73 
BMI (kg·m-2) 26.31± 4.54 24.93 ± 4.17 
Beta-blocker 22 (21%) 12 (25%) 
VO2rest (L·min-1) 0.34 ± 0.12 0.31 ± 0.10 
VO2max ( L·min-
1) 1.76 ± 0.50 1.68 ± 0.48 
VO2R ( L·min-1) 1.42 ± 0.47 1.34 ± 0.45 
Pmax (W) 133 ± 36 132 ± 46 
HRrest (min-1) 79 ± 13 76 ± 16 
HRmax (min-1) 159 ± 21 151 ± 23 
HRR (min-1) 79 ± 21 75 ± 23 
RERmax 1.23 ± 0.11 1.24 ± 0.11 
Hb (g·dL-1) 11.80 ± 1.67 12.12 ± 1.33 
Values are presented as means ± SD or frequencies. 
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TABLE 2a. Calculated exercise intensities before allo-HCT (n=106) in comparison to ACSM values. 
%VO2R 
Reference 
%HRR 
ACSM 
%HRR 
Cancer 
%HRmax 
ACSM 
%HRmax 
Cancer 
%VO2max 
ACSM 
%VO2max 
Cancer 
%Pmax 
Cancer 
%VT (n=104) 
Cancer 
30 30 
24.56±14.10 
CI:21.83-27.26 
P<0.01 
57 
63.14±8.06 
CI:61.60-64.71 
P <0.01 
37 
44.08±4.57 
CI:43.20-44.98 
P <0.01 
29.54±7.77 
CI:28.06-31.05 
83.96±14.43 
CI: 81.14-86.75 
40 40 
34.76±12.41 
CI:32.35-37.15 
P<0.01 
64 
68.13±7.07 
CI:66.77-69.50 
P <0.01 
46 
52.07±3.90 
CI:51.33-52.82 
P <0.01 
39.57±6.85 
CI:38.25-40.90 
99.37±17.13 
CI: 96.02-102.70 
60 60 
55.14±9.66 
CI:53.30-57.01 
P<0.01 
77 
78.12±5.31 
CI:77.08-79.13 
P =0.03 
64 
68.04±2.61 
CI:67.54-68.56 
P <0.01 
59.64±5.64 
CI:58.54-60.71 
130.18±23.40 
CI:125.62-134.73 
90 90 
85.74±8.34 
CI:84.13-87.36 
P<0.01 
96 
93.08±4.21 
CI:92.27-93.88 
P <0.01 
91 
92.00±0.64 
CI:91.89-92.14 
P <0.01 
89.72±6.22 
CI:88.51-90.92 
176.40±33.66 
CI: 169.84-182.95 
 
TABLE 2b. Calculated exercise Intensities 180 d after allo-HCT (n=49) in comparison to ACSM values. 
%VO2R 
Reference 
%HRR 
ACSM 
%HRR 
Cancer 
%HRmax 
ACSM 
%HRmax 
Cancer 
%VO2max 
ACSM 
%VO2max 
Cancer 
%Pmax 
Cancer 
%VT (n=48) 
Cancer 
30 30 
28.75±18.97 
CI:23.30-34.20 
P =0.65 
57 
65.05±11.50 
CI:61.75-8.34 
P <0.01 
37 
44.05±4.40 
CI:42.80-45.33 
P <0.01 
29.60±9.54 
CI:26.83-32.37 
80.42±14.18 
CI: 76.32-84.55 
40 40 
38.34±16.23 
CI:33.69-43.02 
P =0.48 
64 
69.77±9.95 
CI:66.90-72.63 
P <0.01 
46 
52.04±3.76 
CI:50.97-53.14 
P <0.01 
39.63±8.50 
CI:37.18-42.12 
95.23±16.41 
CI: 90.46-100.00 
60 60 
57.56±11.27 
CI:54.32-60.80 
P =0.14 
77 
79.20±7.04 
CI:77.19-81.22 
P =0.03 
64 
68.02±2.52 
CI:67.30-68.76 
P <0.01 
59.73±6.90 
CI:57.73-61.72 
124.82±21.56 
CI:118.56-131.06 
90 90 
86.36±8.00 
CI:84.06-88.67 
P <0.01 
96 
93.38± 4.34 
CI:92.13-94.63 
P <0.01 
91 
92.01±0.63 
CI:91.83-92.20 
P <0.01 
89.86±6.54 
CI:87.96-91.75 
169.20±30.02 
CI: 160.49-177.92 
 
Table 3 shows exercise intensity classes for patients 
prior to and 180 days after allo-HCT derived from 
our sample.  
Comparison to predicted values from standard 
equation 
%HRR values calculated with the equation 220-age 
were significantly lower than the observed values at 
both time points (all P > 0.01). %HRmax values were 
significantly higher than observed values at both 
time points (all P > 0.01, see table 4). 
Effects of potential biasing factors 
Regression analysis revealed that the relationship 
between VO2R and HRmax was not affected by beta-
blocker intake, age, gender, BMI or hemoglobin 
level at all intensities (all P > 0.05).The VO2R-HRR 
relationship was significantly influenced by age (R2 
11.7-12.6%, model: P > 0.026; age: all P > 0.001) in 
all models (except for 90%VO2R) and the VO2R-
VO2max relationship was significantly influenced by 
hemoglobin level (R2 10.4%, model: P > 0.049; Hb: 
all P =.019) in all models. Since no influence of beta-
blocker intake on calculated regressions was 
observed, we included all patients in the analysis. 
 
 
DISCUSSION 
To our knowledge, this is the first study evaluating 
ACSM’s exercise intensity classification in cancer 
patients. Prior to allo-HCT, the %HRR values of our 
patients related to light, moderate or vigorous 
exercise (specified by %VO2R) were significantly 
lower than ACSM recommendations, while %HRmax 
and %VO2max values were significantly higher 
(except for 90% HRmax). Similar results were 
observed 180 days after allo-HCT for%HRmax and 
%VO2max. In contrast, for %HRR the patient values 
did not differ significantly from ACSM 
recommendations (except 90% HRR). Our results 
indicate that the ACSM guidelines concerning 
endurance exercise intensity are not applicable prior 
to allo-HCT, because they did not meet the targeted 
intensity class. 180 days after transplantation, 
only30, 40, and 60% HRR were comparable to 
ACSM recommendations. Furthermore, when 
calculating HRmax with the equation 220-age, values 
for %HRR and %HRmax significantly differed from 
measured values prior to and 180 days after 
transplantation. 
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TABLE 3a. Exercise intensity classes in cancer patients before allo-HCT (n=106). 
Intensity %VO2R (Reference) %HRR %HRmax %VO2max %Pmax %VT 
Light 30 - 39 25 - 34 63 - 67 44 - 51 30 - 38 84 - 98 
Moderate 40 - 59 35 - 54 68 - 77 52 - 67 39 - 59 99 - 129 
Vigorous 60 - 89 55 - 85 78 - 92 68 - 91 60 - 89 130 - 175 
Near-maximal ≥90 ≥ 86 ≥93 ≥92 ≥90 ≥176 
 
TABLE 3b. Exercise intensity classes in cancer patients 180 d after allo-HCT (n=49). 
Intensity %VO2R (Reference) %HRR %HRmax %VO2max %Pmax %VT 
Light 30 - 39 29 - 37 65 - 69 44 - 51 30 - 39 80 - 94 
Moderate 40 - 59 38 - 57 70 - 78 52 - 67 40 - 59 95 - 124 
Vigorous 60 – 89 58 - 85 79 - 92 68 - 91 60 - 89 125 - 168 
Near-maximal ≥90 ≥ 86 ≥93 ≥92 ≥90 ≥169 
 
TABLE 4a. Exercise intensities calculated by equation 
220-age before allo-HCT (n=106). 
%VO2R 
Reference  
%HRR 
(Equation) 
%HRmax 
(Equation) 
30 24.28±16.61
*,** 
CI:19.51-29.05 
58.91±12.34* 
CI:55.35-62.45 
40 32.46±16.05
*,** 
CI:27.86-37.09 
63.23±11.75* 
CI:59.87-66.62 
60 48.82±15.54
*,** 
CI:44.02-53.62 
71.92±11.26*,** 
CI:68.67-75.16 
90 73.36±21.24
*,** 
CI:67.27-79.48 
84.92±12.42*,** 
CI:81.35-88.50 
*sig. difference to measured patients’ values (P<0.05) ** 
sig. difference to ACSM values ( P <0.05) 
 
TABLE 4b. Exercise intensities calculated by equation 
220-age 180 d after allo-HCT (n=49). 
%VO2R 
Reference  
%HRR 
(Equation) 
%HRmax 
(Equation) 
30 22.64±13.54
*,** 
CI:20.03-25.25 
59.57±9.10*,** 
CI:57.80-61.31 
40 31.87±13.25
*,** 
CI:29.33-34.44 
64.32±8.86* 
CI:62.60-66.01 
60 50.33±14.51
*,** 
CI:47.54-53.14 
73.82±8.96*,** 
CI:72.09-75.53 
90 78.04±19.68
*,** 
CI:74.23-81.83 
88.05±10.52*,** 
CI:86.04-90.09 
*sig. difference to measured patients’ values ( P <0.05) 
** sig. difference to ACSM values ( P <0.05) 
 
In healthy people, a dose-response relationship 
between exercise intensity and favorable effects 
occurs. Therefore, exercise prescription should 
ensure a sufficient training stimulus, a reasonable 
control during exercise sessions, but also avoid over-
exertion (10). Thus, in cancer patients it is 
recommended to tailor exercise intensity to 
individual cardiopulmonary fitness levels. However, 
light to moderate intensity is recommended without 
any further definition (4, 27, 30). The Australian 
Association for Exercise and Sport Science 
published in their guidelines for cancer patients 
values of 50-75% VO2max or HRR and 60-80% 
HRmax for moderate intensity, but it remains unclear 
if the data were derived from a cancer population 
(15). In comparison to these guidelines, percentages 
of HRR in our patients were considerably below the 
recommended percentages (50-75% HRR vs. 35-
54% HRR prior to and 38-57% HRR 180 days after) 
for moderate intensity. The application of these 
guidelines would have led to a prescription of higher 
exercise intensity than targeted. Therefore, we 
provide tables with exercise intensities for endurance 
training prescription that were derived from a sample 
of hematological cancer patients. These tables can be 
used to determine exercise intensity prior to and 180 
days after allo-HCT and should be of major clinical 
interest. 
Some studies investigated the relationship between 
HR and VO2 proposed by ACSM in various 
populations. Swain and Leutholzer demonstrated 
that in low-fit subjects, the relationship was 
significantly different from the ACSM values (32), 
whereas Lounana et al. concluded that in highly-
trained subjects the ACSM values were not 
applicable (22). Furthermore, in patients with heart 
disease, (3, 24) chronic obstructive pulmonary 
disease (COPD), (29) and obese individuals (5), the 
proposed percent values from the ACSM 
significantly differed from the calculated percent 
values in the different studies. Moreover, most of the 
studies as well as the ACSM, used pooled group data 
to establish the intensity categories, but it is more 
appropriate to perform a linear regression for each 
subject and then calculate the mean regression 
equation (31). In our analyses we used the 
aforementioned approach and calculated individual 
linear regression equations accordingly.  
Furthermore, the precise reporting of exercise 
intensity is critical to allow exact comparisons 
between training studies. In hematological cancer 
patients during and after HCT, most studies that used 
CPET applied submaximal ergometer or treadmill 
tests (1, 17, 34), very few small studies applied 
maximal tests (6, 14). For training intensity 
prescription, percentages of HRmax and HRR were 
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widely used and the intensity varied between 40% 
and 90% HRmax (11, 14, 19, 28, 34). However, most 
studies used formulas for age-predicted HRmax 
estimates for defining exercise intensities. For 
example, one exercise program beginning 180 days 
after HCT, started at 50-60%HRmax and increased 
intensity up to 70-80 %HRmax (19). By categorizing 
these intensities based on our results, 50-60 %HRmax 
represents a very light intensity (light intensity 
started at 65%), whereas 70-80% HRmax falls in the 
vigorous intensity classification. Another study, 
examining endurance training during chemotherapy, 
used 70% HRmax as an intensity target. This intensity 
was carried out five times in an interval training 
pattern with 3-minutes interval (11). In comparison 
to our data, this would correspond to a moderate-to-
vigorous intensity. Thus, our tables can be used to 
compare the intensities of different exercise studies.  
 
FIGURE 1. Observed and expected linear regression lines for 
VO2R versus HRR, VO2R versus VO2max, and VO2R versus HRmax 
before allo-HCT (n=106). 
Since we observed different values for %HRR 
between the two time points without change in 
VO2max and Pmax values, our results also indicate that 
the relationship between HR and VO2 may have 
changed after intensive treatment. Although the 
results of the paired t-tests did not reach significant 
levels, this change should be considered when 
prescribing exercise intensities. 
Furthermore, we could not find an influence of beta-
blockade on the %VO2R and %HRR, %HRmax and 
%VO2max relationship; therefore, we pooled data 
from patients with and without beta-blocker intake. 
This is consistent with other studies in heart disease 
patients which showed that the aforementioned 
relationships are not affected by beta-blockade (3, 
24). Additionally, one study with healthy subjects 
showed that beta-blockade had no effect on VO2max 
or Pmax (39). This finding indicates that our intensity 
values can be applied to patients regardless of beta-
blocker use, which is relevant since beta-blockers are 
frequently prescribed in cancer patients.  
Despite having a large homogeneous sample, we 
observed a relatively large standard deviation for 
%HRR, indicating that there is some heterogeneity 
in the data. Our regression models revealed influence 
of hemoglobin levels, gender, BMI and age on the 
relationships, therefore these parameters may also be 
important to consider when defining intensity 
prescriptions; when using values estimated from the 
equation 220-age, the variation was even larger. 
However, recommendations on individual level, for 
example using ventilatory thresholds (e.g. VT and 
respiratory compensation point), might be more 
useful for identifying the appropriate exercise 
intensity for an individual patient. When this is not 
possible, our values provided in the tables can be 
used instead. Additionally, we provide information 
about %Pmax and %VT, because these parameters are 
also frequently used for prescribing exercise 
intensity in clinical practice. Our data show that 
%VO2max did not correspond to %Pmax, an important 
finding, since both are frequently used 
interchangeably in practice. Notably, in our patients 
VT occurred at 40% VO2max which is lower than in 
untrained healthy people (23). VT was already 
suggested as an indicator for functional capacity in 
diseased patients when maximal incremental tests 
are not possible (23). However, our maximal CPET 
protocol was not ideal for cancer patients (see below) 
and therefore, these results should be interpreted 
with caution. Further studies should focus on 
determining whether VT as a submaximal parameter 
can be used to give adequate endurance training 
prescriptions for these patients. Additionally, 
prolonged exercise tests should be performed to 
further evaluate our recommended intensity values. 
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Our results are quite important from a clinical 
perspective, because first studies in hematological 
cancer patients after HCT show a potential 
relationship between cardiorespiratory fitness and 
survival (40), underlying the high importance of 
adequate exercise programs that target an optimal 
effect on cardiopulmonary fitness. Furthermore, our 
results underscore the need of individualized 
exercise prescriptions in this patient group. This 
finding complements with other results from our 
group showing that the individual exercise training 
response depends on baseline fitness level in allo-
HCT patients (38). 
One strength of our analysis is the large patient 
population. All patients received allo-HCT, an 
aggressive and demanding treatment which is known 
to profoundly impact physical performance. 
Furthermore, we included two measurement points 
to see if the relationship between HR and VO2 
change over time. Moreover, we used single linear 
regressions to calculate intensity categories. 
However, a methodological limitation is that our 
maximal CPET protocol started at a relatively high 
intensity (50W), therefore the lowest intensity class 
might be imprecisely represented, especially in 
patients with low physical performance. The 
assessment of resting VO2 did not fulfill the criteria 
for resting measurement. However, Cunha et al. did 
not find a significant effect of different resting 
measurement conditions on the regression equation 
between VO2R and HRR (9). 
Conclusion 
It becomes increasingly evident that maintaining 
cardiorespiratory fitness during cancer treatment and 
regaining fitness after treatment improves different 
outcomes, right up to survival. Despite a large body 
of evidence, accurate intensity recommendations 
regarding endurance training do not exist; instead, 
recommendations for healthy subjects are used. Our 
data show that this exercise intensity classification 
may not be valid in hematological cancer patients 
prior to and 180 days after allo-HCT because it may 
result in over- or underestimation of exercise 
intensity. We provide exercise intensity 
classifications that were derived from a large 
population of hematological cancer patients prior to 
and after allo-HCT. These classifications can be used 
to define more appropriate exercise prescriptions in 
hematological cancer patients and to compare 
intensities used in previous studies. Due to 
variability in the observed data, more research is 
needed to further evaluate optimal exercise 
intensities with respect to different treatment 
conditions in hematological cancer patients. 
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ABSTRACT 
Objective: Evidence from randomized controlled trials is growing that exercise interventions are beneficial in 
cancer patients receiving allogeneic stem cell transplantation (allo-HCT). However, information about adherence 
to exercise interventions and exercise contamination in control groups is lacking. This information is crucial for 
the interpretation of study results. We therefore examined the determinants of exercise adherence and 
contamination in different treatment periods during (inpatient) and after (outpatient) allo-HCT. 
Methods: One-hundred-fifty-three patients scheduled for allo-HCT were randomized to a one-year partly 
supervised exercise intervention (endurance and resistance exercise) or a control group (progressive muscle 
relaxation). Adherence was assessed via exercise logs and contamination via physical activity questionnaires.  
Results: Adherence varied between 66% and 78% in different treatment periods. Linear regression models 
revealed that adherence during transplantation period (inpatient) was significantly influenced by fatigue 
(P=0.004), and having children at home (P=0.049). Adherence after discharge was influenced by endurance 
performance (P=0.003); adherence in the last outpatient phase was influenced by baseline exercise (P=0.010) 
and adherence after discharge (P=0.001). Contamination among controls was high with 54% and significantly 
associated with muscle strength (P=0.025) and physical fatigue (P=0.050). 
Conclusions: Exercise adherence in different treatment periods was determined by different variables and 
contamination among controls was evident. These findings may have important implications for correct 
interpretation of randomized exercise intervention trials in cancer patients. 
Keywords: physical activity, cancer, adherence, contamination, transplantation, oncology 
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INTRODUCTION 
Allogeneic stem cell transplantation (allo-HCT) is a 
demanding treatment associated with severe side-
effects, complications such as graft versus host 
disease (GvHD), and high mortality rates (2, 17, 
21). There is a growing body of evidence 
suggesting that exercise interventions may be 
beneficial in reducing side-effects such as fatigue, 
maintaining physical function during treatment, 
enhancing physical fitness after treatment, and 
subsequently improving quality of life (18, 23, 25, 
26). Additionally, our group published recently data 
showing a potential positive effect of exercise on 
prognosis after allo-HCT (27). General exercise 
guidelines for cancer survivors have been published 
(19), however, implementation of exercise 
programs during allo-HCT remains a unique 
challenge, and has been little investigated. In order 
to interpret the results of randomized exercise 
intervention trials (RCT), and to translate programs 
into clinical care, information on adherence to the 
investigated exercise program but also on 
contamination of the control group is important. 
Exercise adherence is the degree to which a person 
fulfills a given exercise prescription (31). Efficacy 
of an exercise intervention can only be investigated 
when patients adhere to the prescribed program. 
Reporting of adherence is inconsistent due to 
heterogeneous definitions. For example, adherence 
has been described as number of exercise sessions 
attended, number of sessions completed, 
percentages of meeting exercise guidelines, or 
exercise minutes per week (11). It is suggested to 
report adherence to each of the FITT criteria 
(frequency, intensity, time and type of exercise) in 
order to demonstrate if patients were able to follow 
the exercise protocol, and to describe the exercise 
dose received (24). Further, it is still unclear 
whether adherence rates are different in different 
treatment phases (during vs. after treatment) and in 
supervised vs. home-based settings. A recent 
review revealed that 73% of all supervised studies 
in the transplant setting did not report adherence 
rates at all (9). 
An equally important, but far less acknowledged 
problem of exercise RCTs is the contamination of 
the control group. Contamination refers to the 
extent to which the control group has adopted the 
intervention and started to exercise on their own. 
For example, a home-based walking intervention in 
breast cancer patients seemed to have no effect on 
fatigue, but further analyses revealed that 50% of 
control group (CG) subjects were exercising during 
the study period, and about 30% of exercise group 
(EG) subjects did not maintain the prescribed 
exercise program of 90 min walking per week. 
When the authors compared the high walking (more 
than 90 min/week) to the low walking (less than 
90min/week) group they were still able to detect 
significant differences between groups (15). 
However, per-protocol analysis implicates a reverse 
causation problem.  
Following the intention-to-treat principle of RCTs, 
poor adherence on one side and high contamination 
on the other side may diminish a potential true 
effect of the prescribed exercise intervention 
towards null (30). Furthermore, adherence and 
contamination are influenced by the enrolled 
population. A low recruitment rate in combination 
with a good retention might reflect the problem of 
recruiting a selective sample, likely over-
representing subjects with generally better health, 
higher exercise-affinity, motivation or self-efficacy. 
However, patients with generally low health and 
feeling that they cannot carry out the exercise 
program may refuse to participate (9). This 
selection may limit generalizability of findings. 
Therefore, we analyzed data from a large ongoing 
RCT (PETRA-Study) (28) in allo-HCT patients to 
gain a deeper insight into determinants of both, 
adherence and contamination, in in- and outpatient 
treatment phases. Understanding these data may 
help to develop more individualized exercise 
recommendations, achieve better adherence, 
consequently improving outcomes, and enhance 
interpretation of study results. 
METHODS 
Design and Participants 
The PETRA study is a large ongoing RCT in 256 
hematological cancer patients during and after allo-
HCT with 2-year overall survival as primary 
outcome. The study design has been reported 
elsewhere (28). The study is registered at 
ClinicalTrials.gov (NCT01374399) and approved 
by the local ethic committees. Here, we analyzed 
the data of the first 153 patients included in the 
PETRA study. 
Interventions  
Briefly, patients assigned to the EG started the one-
year intervention program (endurance and 
resistance exercise, 3-5x/week) at the first day of 
conditioning for allo-HCT (chemotherapy, total 
body irradiation) in isolation units at the hospital. 
During this first period three of the weekly sessions 
were supervised. After hospital discharge patients 
continued the exercise program home-based (3-
5x/week) and were called regularly per phone to 
check on their adherence. The exercise program 
was individually adapted and tailored, based on the 
intervention program evaluated in our previous 
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included to enhance adherence. Contraindications 
for exercise were low thrombocyte counts (< 15µl), 
infections/ fever, and dizziness.  
Patients assigned to the CG received a muscle 
relaxation program (according to Jacobson) (1) with 
three supervised sessions per week during inpatient 
stay, and continued the program home-based, 
including regular phone calls. 
Measurements 
Assessment points for this analysis were prior allo-
HCT, at the day of discharge, 100 days and 180 
days after allo-HCT (see figure 1). To assess 
adherence, patients in the EG filled out exercise 
logs at each training day. In these logs patients 
could fill in the total exercise duration per day, 
what type of exercise they performed (endurance, 
resistance, or both), and whether they had to stop 
exercise prematurely due to specific reasons, e.g. 
fatigue, nausea or lack of motivation, or record why 
they could not perform the program (only after day 
100). Patients were also asked to document exercise 
activities carried out during additional supportive 
care programs (e.g. physiotherapy, rehabilitation) in 
the exercise log. During supervised exercise 
sessions, the study personnel documented reasons if 
exercise could not be performed due to medical 
contraindications. Exercise logs were returned at 
each assessment time point.  
To evaluate exercise contamination in the CG at 
180 days after transplantation, patients were asked 
to self-report the amount of physical activity in a 
typical week since the last assessment via 
questionnaire. 
Details of our physical performance assessment 
procedures and patient-reported outcomes (PROs) 
were described elsewhere (28). Briefly, we assessed 
physical performance with the 6-minute walk test 
(6MWT), and isometric muscle strength with a 
hand-held dynamometer. For PROs we used 
standardized questionnaires (MFI, EORTC QLQ). 
Baseline characteristics were assessed via 
questionnaires and medical chart reviews, and 
incidence and severity of GvHD were documented 
by attending physicians.  
             FIGURE 1. Observed intervention periods. 
 Statistical analysis 
Baseline characteristics and other group 
characteristics were compared using t-tests for 
continuous data and Chi-square test or Fisher’s 
exact test for categorical data. Adherence was 
calculated for each intervention period as total 
minutes of exercise in this period divided by the 
period length (in weeks), i.e. min/week. For 
contamination we calculated total hours of walking, 
sport-activities and cycling per week, based on our 
questionnaire at the time point 180 days after allo-
HCT. Linear regression models were calculated 
with adherence and contamination as dependent 
variables and potentially relevant factors, assessed 
at baseline and at each measurement point as 
independent variables, including: (1) demographic 
and medical data: age, gender, education (4 
categories), family history, time since diagnosis, 
and development of GvHD larger than grade 1; (2) 
health-related fitness variables: body-mass-index 
(BMI), submaximal endurance capacity (walking 
distance), knee-extensor muscle strength, physical 
activity (walking, cycling, sport-activities) at 
baseline and during adolescence (sport-activity); 
and (3) PROs: general and physical fatigue (MFI), 
different quality of life domains, e.g. physical 
functioning, role functioning, and general quality of 
life (EORTC). In consideration of multicollinearity, 
we aimed to identify the most relevant 
determinants. To explore the stability of the results, 
several a priori plausible sets of covariates were 
calculated. Variables that neither showed 
significant associations with the dependent variable 
nor had confounding effects on other covariates 
were dropped from the final model (13). For each 
study period a separate model for adherence was 
calculated. We log-transformed the dependent 
variables adherence to fulfill the normality 
assumption of residues. As a secondary sensitivity 
analysis, for regression models, missing adherence 
values were imputed using information obtained 
during regular phone calls. Reported p-values are 
two-sided with significant level of 0.05. SAS 
statistical software version 9.3 (SAS Institute, Cary, 
NC, USA) was used.  
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RESULTS 
Recruitment and retention 
Recruitment took place from February 2011 until 
November 2013 (see figure 2), and 153 patients 
were randomized at the day of admission. Baseline 
characteristics of the study population are described 
in table 1. Since the study is still ongoing, 12 
patients had not yet reached the 180 day 
measurement at the time of data analysis. Primary 
reasons for drop-out were no interest in muscle 
relaxation (CG), and feeling to be too overburdened 
to perform the physical tests. 
Adherence to the exercise intervention  
Adherence data for three different study periods are 
presented in table 2, based on the returned logs. 
Main reasons for not exercising during the first 
study period were fever, low thrombocyte counts 
and severe side-effects from conditioning therapy 
(inpatient setting during transplantation process, 
isolation rooms). 
Determinants for exercise adherence 
Determinants for higher adherence during inpatient 
stay were low physical fatigue (MFI, P=0.004), and 
having children at home (P=0.049). Determinant for 
a higher adherence after discharge up to day 100 
was a better submaximal endurance performance at 
discharge (6 MWT, P=0.003), when controlling for 
emotional functioning (P=0.189). For adherence 
between day 100 up to day 180 significant 
determinants were sport-activity at baseline 
(P=0.010) and higher exercise adherence after 
discharge (P=0.001). The models for the three time 
points explained 16%, 21% and 55% of variance, 
respectively (table 3). Variables not listed in the 
table (e.g. demographics and medical data) showed 
no significant associations with adherence, neither 
in the univariate nor in the multivariate adjusted 
models. When using the imputed adherence 
variables, no significant changes in determinants 
were observed.  
Contamination of control group 
One-hundred-eighty days after allo-HCT, 26 
patients (54.2 %) of the CG stated that they were 
currently doing some kind of sport-activity, and 43 
patients (89.6 %) stated that they were walking on a 
regular basis. Time spent walking was on median 
4.0 (interquartile range: 2.0-7.5) hours per week. 
Only 5 patients (22.9%) of the CG reported no 
activity at all. Eleven CG patients (23.9%) received 
outpatient physiotherapy, 5 patients (10.9%) 
received inpatient rehabilitation, and one patient 
(2.2%) outpatient rehabilitation. For comparison, in 
the EG 10 patients (20%), 3 patients (6%) and 2 
patients (4%) received these additional support 
activities, respectively. 
Determinants for contamination 
Determinants for contamination were higher 
isometric muscle strength (P=0.025) and lower 
physical fatigue (P=0.050) 180 days after 
transplantation. Total variance that could be 
explained was 29.4% (P=0.001). The model is 
presented in table 4. 
DISCUSSION 
To our knowledge, this is the first study that 
examined the determinants of exercise adherence 
and contamination in an RCT in the transplantation 
setting. We could define different determinants for 
adherence in different treatment phases. Adherence 
to inpatient  exercise was better among patients 
having children at home and lower fatigue, whereas  
sport-activity before transplantation, and higher 
endurance performance and high adherence directly 
after discharge were significant determinants for 
higher adherence in the outpatient home-based 
settings. Significant determinants for contamination 
among controls were high isometric muscle 
strength and low physical fatigue.  
In order to translate exercise programs into clinical 
practice it is crucial to give detailed information 
about adherence and to demonstrate that the 
prescribed exercise intervention could be performed 
by the individual patient. A recent review 
summarized, that the majority of all supervised 
studies in the transplant setting did not report 
adherence data (9).  Regarding allo-HCT patients 
only, three RCTs reported adherence rates: The first 
study by Jarden et al. was conducted during 
hospital stay for allo-HCT (4-6 weeks) and they 
reported 90% adherence (defined as attendance) to 
their five times per week supervised multimodal 
exercise program (10). Another study in 100 allo-
HCT patients examining a daily unsupervised 
walking intervention (30 min) during and after allo-
HCT reported an adherence rate of only 24% (7). In 
comparison, in a previous RCT conducted by our 
group we received adherence rates of 83 to 91% 
prior, during and after treatment (25). 
Since our observed intervention period in this study 
was relatively long and took place in different 
clinical settings, we looked at exercise adherence 
during the inpatient period, the outpatient periods 
till day 100 and till day 180 after allo-HCT 
separately. With regard to exercise adherence, 66 to 
78% of all patients were able to exercise more than 
three times per week, and exercise duration 
increased from 89 to 199 min during the entire 
studied period. As expected, during inpatient period 
exercise frequency and duration was lowest, 
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BMI, body mass index; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; MDS, 
myelodysplastic syndrome; CML, chronic myeloid leukemia; MPS, myeloproliferatory syndrome; allo-HCT, allogeneic hematopoietic stem 
cell transplantation; auto-HCT, autologous hematopoietic stem cell transplantation 
 
*Chi2-test, only significant (P>0.05) P-values listed 
 
TABLE 1: Baseline characteristic of study population 
 Exercise group Control group P 
TOTAL n,%  76 100% 77 100%  
Age, mean (SD)  53.4 (10.1) 54.2 (11.7)  
Gender, n % female 24 31.6% 26 33.8%  
male 52 68.4% 51 66.2%  
BMI, mean (SD)  26.6 (4.5) 25.7 (4.6)  
Married, n % no 5 6.6% 7 9.1%  
yes 71 93.4% 70 90.9%  
Level of education, n % low 16 21.1% 15 19.5%  
medium 23 30.3% 12 15.6% <0.001* 
high 17 22.4% 25 32.5%  
academic 19 25.0% 25 32.5%  
miss 1 1.3% 0 0%  
Children at home, n % yes 56 73.7% 53 68.8%  
no 19 25.0% 21 27.3%  
missing 1 1.3% 3 3.9%  
Any sports currently, n % no 53 69.7% 49 63.6%  
yes 23 30.3% 28 36.4%  
Walking regularly currently, n % no 15 19.7% 14 18.2%  
yes 61 80.3% 63 81.8%  
Walking h/week, currently, mean (SD)  3.5 (6.7) 3.4 (3.1)  
Cycling regularly currently, n % no 59 77.6% 51 66.2%  
yes 17 22.4% 26 33.8%  
Sports in childhood, n % no sports 25 32.9% 19 24.7%  
any sports 24 31.6% 28 36.4%  
competitive 27 35.5% 30 39.0%  
Current smoking, n % no 69 90.8% 72 93.5%  
yes 4 5.3% 5 6.5%  
missing 3 3.9% 0 0%  
Karnofsky Performance Score,  
median (Q1, Q3) 
 90.0 (90.0, 
100.0) 
90.0 (90.0, 
100.0) 
 
Time since diagnosis,  
median (Q1,Q3) 
 11.9 (5.4, 
42.8) 
15.6 (4.8, 
59.4) 
 
Complete remission, n % no 45 59.2% 41 53.2%  
yes 29 38.2% 33 42.9%  
missing 2 2.6% 3 3.9%  
Diagnosis 
 AML 
 ALL 
 Lymphoma/CLL 
 MDS 
 CML/MPS 
 Multiple Myeloma 
 Other 
 Aplastic Syndrome 
  
20 
4 
28 
11 
2 
9 
2 
0 
 
13.0% 
2.6% 
18.3% 
7.2% 
1.3% 
5.9% 
1.3% 
0% 
 
25 
5 
26 
8 
3 
9 
0 
1 
 
16.4% 
3.3% 
16.9% 
5.1% 
1.9% 
5.9% 
0% 
0.6% 
 
Previous allo-HCT, n %  4 5.3% 3 3.9%  
Previous auto-HCT, n %  18 23.7% 14 18.2%  
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FIGURE 2. Patient flow chart showing the numbers of patients who were recruited and randomized and run 
through the assessment points. 
 
noticing, that this period includes the phase of 
severe side-effects contraindicating exercise. 
General exercise guidelines for cancer survivors 
recommend 150 min moderate activity per week 
(19). After discharge 40%, and after day 100 60% 
of patients in the exercise group reached this 
recommendation. We observed, however, a large 
variation in exercise duration between patients.  
Due to the fact that most studies reported 
frequencies of sessions attended, the actual volume 
or dose of exercise performed remained unclear. 
However, exact information is necessary to 
determine a possible dose-response effect. 
Therefore, we presented additional data on exercise 
duration. Furthermore, to gain a better 
understanding of poor adherence, the reasons for a 
premature stopping of the exercise sessions were 
considered. Interestingly, fatigue was in all phases 
the most frequent reason why exercise was 
terminated. High level of baseline fatigue was also 
significantly associated with low adherence during 
inpatient stay, and a significant determinant for low 
exercise contamination 180 days after allo-HCT.  
Our data provided a unique possibility to study 
determinants of adherence in the course of different 
periods and settings. We found that less fatigue, 
higher endurance performance, sport-activity before 
transplantation and high adherence directly after 
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TABLE 2: Adherence in different study periods 
 Inpatient Outpatient  
≤ day100 
Outpatient  
> day100 
TOTAL patients*,  n,% 74 100% 58 100% 45 100% 
Training days/week, median (Q1, Q3) 
Strength training 
Aerobic training 
Mixed training 
3.5 
1.2 
0.8 
1.0 
(2.6, 4.2) 
(0.7, 1.6) 
(0.5, 1.3) 
(0.4, 1.8) 
3.4 
1.6 
0.9 
0.5 
(2.8, 4.8) 
(0.9, 2.2) 
(0.5, 1.6) 
(0.2, 1.3) 
4.3 
0.9 
2.0 
0.5 
(3.5, 5.2) 
(0.4, 1.5) 
(1.4, 2.9) 
(0.2, 1.3) 
Training on more than 3 days/ week, n,% 49 66.2% 38 65.4% 35 77.8% 
Duration minutes/week, mean (SD) 89.2 (51.2) 147.6 (99.4) 198.8 (107.3) 
Meeting exercise guidelines (150 min/ week), n,% 5 6.8% 23 39.7% 27 60.0% 
Percentage of incomplete sessions**, 
median (Q1, Q3) 
12.9 (0.0, 24.0) 8.8 (1.5, 23.8) - - 
Reported reasons***: 
Fatigue 
Nausea 
Pain 
Lack of motivation 
Time constraints 
Others 
  
63.7% 
18.8% 
14.8% 
9.9% 
- 
18.4% 
  
44.8% 
8.2% 
27.9% 
8.7% 
2.6% 
15.6% 
  
31.3% 
11.1% 
15.1% 
11.7% 
9.4% 
44.3% 
* Data presented are based on the returned logs 
** Only recorded in the first two periods 
*** In the last period reasons for not exercising were reported. In the other periods reasons for exercise termination 
were reported 
discharge were significant determinants for higher 
adherence in different treatment periods. The 
models explained 16%, 21% and 55% of variance 
respectively. These results are in line with a current 
review about determinants of adherence in other 
cancer populations. The authors reported moderate 
evidence for exercise history as consistent 
determinant, whereas other variables e.g. age, 
gender, fitness, education and psychological 
variables, yielded inconsistent results. They 
concluded that still little is known about 
determinants of adherence in different treatment 
phases and various settings (11). In a study in 
lymphoma patients, past exercise was also observed 
as significant predictor of adherence (6). 
Remarkably, GvHD, known as major complication 
after allo-HCT (8), and having profound impact on 
physical function (14), did not show to influence 
adherence in our study. This is in contrast to a 
retrospective trial where only 54% of patients with 
GvHD could adhere to a supervised exercise 
program (16). This result illustrates the challenging 
patient group and the need to individually adapt 
exercise programs. 
A large proportion of the control group adopted 
exercise during the study. 89% of control group 
patients stated 180 days after allo-HCT that they 
were walking on a regular basis, 54% stated that 
they were doing some kind of sport-activity. Only 
few studies reported data on contamination and 
since results have been very inconsistent, a possible 
blurring effect of exercise contamination on the 
results of published RCTs is unknown. In the 
transplant setting only one RCT reported 
contamination, which was with 7.5% much lower 
than in our study (12). Comparable to our setting, 
an RCT in colorectal cancer survivors post-
treatment examining a home-based walking 
program, reported a contamination rate of 52% (3), 
whereas another home-based mixed exercise 
program during active treatment in a mixed cancer 
population (mainly breast and prostate cancer) 
reported a contamination rate of only 12% (20).  A 
possible explanation for contamination in our study 
could be the growing awareness of patients, 
clinicians and physiotherapists of the benefits of 
exercise after HCT. The positive results of our 
previous RCT (25, 29), conducted in the same 
hospital, might have further raised the knowledge 
among the clinical personnel regarding exercise 
during and after allo-HCT. We feel that the 
encouragement by physicians to engage in physical 
activity has increased substantially, and patients 
proactively ask for advice. Important to note, the 
control group had a significantly higher education 
level, which is known to lead to higher physical 
activity levels after cancer diagnosis (22). 
Significant determinants for contamination, i.e. for 
high activity 180 days after allo-HCT, were high 
isometric muscle strength and low physical fatigue, 
which explained 29% of variance. Comparing our 
results to other studies is complicated due to the 
fact that different predictors were included. For 
example, in the previously mentioned study with 
colorectal cancer survivors, intention and baseline
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exercise stage of change (driven from the trans-
theoretical model) were significant predictors for 
exercise contamination. However, demographics, 
past exercise, fitness, and medical variables had no 
influence (4). Conversely, in the second mentioned 
study past exercise history was the only significant 
predictor (20). Likely, the contamination of the 
control group depends on the setting and type of 
intervention. 
Detailed information about recruitment rates are 
rarely reported in the setting of hematological 
cancer patients. In contrast to our relatively high 
recruitment rate of 73%, other studies included 25 
to 91% of eligible patients (5, 10, 12). Since the 
main intervention mode of the PETRA study is a 
home-based program, and the intervention duration 
(one year) is quite long, we think that recruitment 
works well and provides a representative sample of 
the underlying population.  
Strengths of our study comprise a large 
representative sample and long intervention 
duration, including different treatment periods. 
Furthermore, this is the first study that examined 
adherence during inpatient and outpatient setting in 
more detail, and investigated determinants for 
adherence and contamination in the transplant 
setting. However, it should be noted that there are 
limitations to this study. Adherence and physical 
activity were assessed via self-report; therefore 
over- or underreporting might have biased our 
results. Also, we have only data of physical activity 
(contamination) 180 days after transplantation. Data 
on type of disease, previous treatment modalities 
and intensity of conditioning chemotherapy prior 
allo-HCT were not considered as determinants in 
the models. However, we included time since 
diagnosis as a predictor variable.  
In summary, the exercise adherence rate was 
between 66 and 77% in the different periods, and 
we were able to identify various determinants for 
adherence in the three studied intervention periods. 
Whereas fatigue was an important predictor for 
adherence during inpatient setting, physical 
performance and physical activity before 
transplantation were determinants for the adherence 
in the home-based settings. These are important 
information when translating exercise programs 
into clinical practice. Future research should focus 
on improving adherence in patients who have 
problems to adopt regular exercise, thus optimizing 
individually tailored programs. However, 
contamination of the control group is a substantial 
issue and should be considered in all ongoing and 
future exercise trials. 
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6 General Discussion 
This thesis provides results from two large RCTs in hematological cancer patients during and 
after allo-HCT. The aim of this work was to enhance exercise prescriptions in allo-HCT 
patients and to give practical guidelines for designing exercise interventions and future 
interpretation of study findings. 
This chapter summarizes the main findings and discusses the results in the light of the 
existing literature and methodological aspects. The chapter ends with clinical implications and 
suggestions for future research. 
 
6.1 Summary Main Findings 
In the first manuscript (chapter 2), we examined the impact of baseline physical performance 
on exercise response in the experimental group of the first RCT. When comparing the changes 
in physical performance of initially fit classified patients to unfit classified patients, we 
observed a significantly different development in both patient groups. Whereas the initially fit 
patients lost 31% of their strength of the knee-extensors, the unfit patients lost only 1% 
(p<.01). For endurance capacity, the initially fit patients lost 4%, whereas the unfit patients 
gained 13% (p<.05). The individual percent change was significantly different for all 
measures of physical performance. We concluded that initially unfit patients can exercise 
safely and may benefit more from exercise during and directly after allo-HCT than initially fit 
patients. This finding is of major clinical relevance because exercise is often not 
recommended in patients with poor health status and in deconditioned individuals. However, 
it might be that initially fit patients need a more intense exercise recommendation. 
In the second manuscript (chapter 3), we described the rationale and the study design and all 
study procedures of our ongoing RCT called PETRA study. The PETRA study is a large 
exercise intervention trial during and up to one year after allo-HCT and will include 256 
patients. The primary endpoint is overall survival after two years; secondary endpoints 
include for example physical performance, body composition, fatigue, quality of life, 
depression, distress, severity of side-effects, e.g. GvHD, effect on hematological and 
immunological reconstitution and inflammatory parameters. The experimental group performs 
a combined moderate intensity program consisting of endurance and resistance exercises, 
which is partly supervised during inpatient stays and self-directed home-based during 
outpatient stays. The control group receives a comparable program, but with progressive 
muscle relaxation to reduce social bias. The strengths of the study are the large sample size, 
the comprehensive assessment procedures, including gold-standard assessment procedures for 
assessing physical performance, and the intervention for the control group. This study 
provides a large data base to examine not only the effects on primary and secondary 
endpoints, but will give answers to highly important questions regarding optimizing exercise 
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interventions and exercise prescriptions in cancer patients. The two following manuscripts are 
based on data of the PETRA study. 
In the third manuscript (chapter 4), we examined maximal cardiopulmonary exercise test 
(CPET) data of 106 PETRA patients prior to and 180 days after allo-HCT. We evaluated the 
relationship between %VO2reserve and %HRR, %HRmax and %VO2max, and compared 
calculated endurance training intensities to given data from the ACSM in order to examine, if 
the currently used prescription from the ACSM is valid in allo-HCT patients. We observed 
that the ACSM’s exercise intensity recommendations for endurance training might not meet 
the targeted intensity classes, with the exception of %HRR 180 days after allo-HCT, resulting 
in over- or under-estimation of exercise intensity. In addition, we provided a table with 
exercise intensity classes obtained in hematological cancer patients that can be used to give 
exercise prescriptions, and to compare intensities of other studies. Furthermore, we found out 
that applying exercise intensity recommendations based on percentages of the commonly used 
equation 220-age also did not provide appropriate intensities. This was the first study that 
compared the widely used ACSM intensity prescriptions with a population of cancer patients. 
In the last manuscript (chapter 5), we proved that our recruitment of the first 153 patients in 
the PETRA study was excellent (73%), providing us with a representative sample of this 
challenging population. Adherence rates were acceptable in all three studied periods 
(inpatient, outpatient up to day 100, day 100 up to day 180), ranging from 66 to 77% (89 to 
199 min/ week). Most important determinants for adherence were fatigue (p=.004), physical 
performance (p=.003) and prior exercise engagement (p=.010). The models could explain 
16%, 21%, and 55% of variance respectively. However, we also faced some problems that 
may negatively affect further study results. Exercise contamination of the control group was 
evident in 54% (89% were walking on a regular basis). Determinants for exercise 
contamination were higher muscle strength (p=.025) and less fatigue (p=.050). Total variance 
explained was 29%. The results give important implications for future exercise trials and data 
analysis.  
 
6.2 Discussion 
So far, the PETRA study is the largest randomized controlled exercise intervention trial in 
HCT patients. RCTs are known as gold-standard in evaluating interventions. The study 
encompasses two distinct periods of the previously introduced PEACE cancer control 
framework: during and after treatment; in some cases an additional palliative care or 
resumption period is included. This provides a unique opportunity to examine effects of 
exercise throughout the whole transplantation, and rehabilitation process. Other larger studies 
in this field used mixed populations of allogeneic and autologous transplanted patients and 
applied the intervention either during or after hospital stay (1, 2). Due to the different nature 
and biology of allogeneic and autologous transplantation process (autologous HCT requires 
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no immune suppression and has no risk of GvHD since the transplanted cells originate from 
the patient itself), the recovery process after HCT may be quite different between both 
transplanted groups; this complicates the conclusions drawn in previous studies from these 
heterogeneous populations.  
The rationale for the PETRA study was a retrospective analysis of survival data of our first 
RCT, where a possible effect of exercise on overall survival could be shown (3). Additionally 
to the first RCT (4), the intervention duration in the PETRA study was extended up to one 
year, and a one year follow-up measurement time point was included. In addition, we 
stratified our randomisation process on relevant prognostic factors (e.g. remission state), and 
we included gold-standard physical performance measurements (CPET, isometric and 
isokinetic muscle strength measurements and accelerometers) to assess more objective fitness 
parameters in order to enhance internal validity. The additional use of these assessment 
procedures gives us the possibility to compare the common used procedures, e.g. six-minute 
walk test, with the gold-standard methods. This will give us important information about 
interpretation of physical performance data in the future. Furthermore, detailed GvHD 
documentation and blood samples at each measurement time point were included to study 
more mechanistic questions (see chapter 3).  
A first analysis of the PETRA data revealed a representative sample which allows 
generalisation of outcomes. 73% of eligible patients could be included in the trial, a relatively 
high number compared with other studies. For example, Knols et al. included only 41% in 
their supervised intervention after HCT (2), Shelton et al. included 24% (5) and Courneya et 
al. included only 26% of eligible lymphoma patients (9% of all screened patients) in their 
HELP-trial (6). The dilemma of recruiting only highly motivated patients and patients in good 
health status, who are more likely to adhere to a given exercise prescription, versus a 
representative sample, including also patients with more co-morbidities and side-effects, was 
discussed in chapter 5. Thus, patients who do not like exercise or do not feel that they can 
master the program may refuse participation right from the beginning and limit attrition.  
A recent review described the retention and adherence in exercise studies in the transplant 
setting. From 20 included studies, mean sample size was 49.9 (SD 39.38), providing samples 
of 10 to 135 patients. The retention was surprisingly high (82%) and 24% of drop-out reasons 
were attributed to recurrent disease (7). However, particularly in small studies, the retention 
was up to 100%, indicating a very selective sample. In the PETRA study, recurrence was no 
reason for drop-out or not performing our testing procedures (data not shown). Depending on 
the type of disease recurrence and the following therapy, patients were able (after adaption) to 
continue our exercise program. However, due to the small number of recurrent disease during 
the first 180 days we did not perform any statistical analysis, for example, to examine the 
effect of recurrence on adherence.  
The inclusion of a selective sample results in an emphasis on internal validity. On the other 
hand, however, it limits external validity of findings (generalisability) and may confound 
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translation of evidence based exercise programs into clinical practice. Courneya et al. 
determined adherence as one of the key differences between efficacy (high adherence) and 
effectiveness (real world conditions, lower adherence) trials (8). Therefore, our adherence 
data must be seen in the light of the underlying population and the degree of supervision, 
since supervised exercise interventions may have higher adherence (9). Unfortunately, the 
study by Shelton et al. did not report adherence rates in the compared supervised and 
unsupervised exercise groups and therefore this study gives no further insight into possible 
effects of supervision in allo-HCT patients (5). In the PETRA study, adherence was 
acceptable with 66% during allo-HCT, 65% and 77% after allo-HCT, but lower than in 
comparable studies. Exercise duration increased from 89 minutes per week to 199 minutes per 
week. In our first RCT we reached adherence rates between 83% and 91% (4), and another 
study, examining effects of a supervised multimodal exercise intervention in allo-HCT during 
hospital stay, reported adherence ranging from 80 to 97% (10). Both studies had shorter total 
intervention duration, known to enhance adherence. Furthermore, when comparing PETRA 
adherence data to our first RCT, it might be that in the first study selection bias was present, 
since we included a smaller proportion of patients transplanted in the two centers. In 
comparison to the length of intervention investigated within the PETRA study (6 months), a 
pilot study in 24 multiple myeloma patients receiving autologous HCT which investigated an 
unsupervised home-based exercise program achieved an adherence of 75% (11). Another 8-
week feasibility study in deconditioned cancer survivors after chemotherapy reported 
comparable adherence to a supervised aerobic exercise of 78% (12).  
However, due to a lacking standard in reporting adherence data, it is still difficult to compare 
these data. The most recent review by Kampshoff et al. dealt with adherence and its 
determinants and summarized the large variety of different measures applied to describe 
adherence. Studies used for example percentage of the prescribed number of sessions 
attended, number of completed exercise sessions, average minutes of exercise per week, or 
meeting exercise goals (13). Furthermore, the CONSORT Statement, used as a worldwide 
standard to report RCTs, does not require that authors report information about adherence to 
the tested intervention (14). Therefore, reporting and interpreting adherence data remains 
insufficient. In our analysis (chapter 5) we reported adherence referring to the previous 
introduced FITT criteria. We described the number of exercise days/sessions per week and 
exercise duration (minutes per week). We distinguished between endurance and resistance 
exercise sessions and could discriminate between different periods during and after treatment. 
Additionally, we described how many patients were able to exercise more often than the 
prescribed minimum of three exercise days per week, and how many patients could meet the 
recommended exercise duration of 150 min exercise per week (15). This detailed adherence 
description is important for a better comparison between studies and reproducibility. 
Moreover, it is crucial to allow conclusions about the efficacy of intervention program, and if 
a given exercise program might be successful when translated into standard care. However, a 
limitation is that we were not able to give clear adherence to exercise intensity performed, 
since the main intervention mode was a self-directed home-based training. Patients received 
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the clear advice which intensity they should target using the BORG RPE-scale (16), and the 
intensity prescription was re-evaluated during the regular phone calls, but we do not have a 
consistent documentation of intensity performed. 
We also examined possible determinants for adherence in different treatment periods (PEACE 
framework). To our knowledge, this was the first analysis performed in the HCT setting 
(chapter 5). Our results were comparable to other studies in different cancer populations that 
found fatigue, physical performance and exercise history as significant predictors for 
adherence (13, 17-19). However, all previous studies examined predictors of adherence in one 
distinct setting, whereas our study looked at determinants in different treatment phases 
(during and after allo-HCT) and different delivery modes (supervised and home-based). In the 
first period, our regression model explained 16% of variance of exercise duration, suggesting 
that during intense treatment and supervision there are other more important factors than those 
examined. Potential factors may be, for instance, dose of the conditioning chemotherapy prior 
allo-HCT, previous treatment modalities or co-morbidities. We will consider these factors in 
further analyses. Explained variance of adherence was 21% after discharge up to day 100. Our 
results proposed that a good physical performance at discharge heavily contributes to a better 
adherence to the self-directed exercise program at home. This finding indicates even more 
that exercise interventions during HCT or even prior HCT are important. Our study could 
confirm the results of other studies that patients with exercise experience prior treatment had 
higher adherence (13). Explained variance in this period was 55%. A further new result was 
that having GvHD (greater than grade 1) did not influence the adherence, indicating that 
patients suffering from this complication are able to exercise. This is an important finding 
since there is only one retrospective study that describes the adherence of patients suffering 
from GvHD to a four-week exercise-based rehabilitation program. In this study only 54% of 
all 59 patients could complete 80% of the prescribed sessions (20). Furthermore, another 
review about determinants of adherence focused only on motivational and behavioral factors 
and concluded that the found predictors e.g. exercise stage of change derived from the 
transtheoretical model of behavior change, were weak predictors (21).  
Providing information on determinants is important information to improve future study 
designs and to translate programs into clinical care. Our results indicated that special attention 
to patients with high fatigue levels and low endurance performance is needed to enhance 
adherence in these subgroups. The recent review by Kampshoff et al. identified all examined 
determinants of adherence (the 12 included studies investigated associations with 71 
determinants!), but only for exercise history moderate evidence could be found. The authors 
pointed out that methodological issues of the included studies, e.g. small sample size and 
selection bias, might have resulted in insignificant findings in the performed studies (13). 
Moreover, the insufficient description of adherence of previous studies makes it impossible at 
this research state to investigate determinants of adherence regarding type, frequency, 
intensity and delivery mode (e.g. supervised, home-based) across available studies. 
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Beside adherence, we further investigated a far less acknowledged problem of exercise 
intervention trials, a possible contamination of the control group. As described in chapter 5, 
contamination refers to an exercise engagement in the control group. Only few studies 
elucidated this possible behavior, although it is known to cause a delusion of the treatment 
effect which may make it impossible to show any positive results based on an intention-to-
treat principle (22, 23). The recent review about exercise oncology research from Jones & 
Alfano elaborated current research gaps and constituted the consideration of exercise 
contamination in the control group as an issue that needs to be considered in future trials (24). 
We assessed contamination via questionnaire at day 180 after allo-HCT. As presented in 
chapter 5, 89.6% of control group participants stated that they were walking on a regular basis 
(mean duration 4 hours per week), and 54.2% listed that they were doing some kind of 
sportive activity. When comparing these data to our intervention group, the most frequent 
exercise performed at this time point was endurance exercise (mainly performed as walking). 
Given the long duration of weekly walking activity stated by the control group, we think that 
the exercise dose received was quite similar in both groups in terms of endurance exercise 
duration. This information will give us additional information when analyzing the primary 
and secondary outcome parameters of the PETRA study (see chapter 3), and may help to 
explain possible low intervention effects.  
However, assessment methods of both, adherence and contamination rely on self-report, and 
for contamination a recall bias may be affecting the results since the patients needed to 
describe activities retrospectively (25, 26). Therefore, our objectively assessed physical 
activity data obtained with accelerometers at each measurement time point will give important 
information not only on walking duration, but also on achieved intensity (metabolic 
equivalent, METs). However, one need to consider that resistance training activities cannot be 
determined using accelerometers. In our first RCT, physical activity was measured with 
pedometers. Interestingly, prior to and after transplantation the control group reached non-
significantly more steps than the exercise group (4). Courneya et al. described that 
participants of the exercise group might compensate for the exercise sessions by reducing 
other forms of physical activity in daily living (17). 
In the PETRA study, significant determinants for exercise contamination were high isometric 
muscle strength and low physical fatigue levels; total variance that could be explained was 
29.4% (see chapter 5). This result supports our findings regarding determinants for adherence, 
since a physical performance measurement and fatigue also strongly influence adherence. 
These consistent results underline the importance to consider these aspects when prescribing 
exercise programs in allo-HCT patients. Possible reasons for the high contamination rate were 
discussed in chapter 5, and the question arises if there are any solutions that can help to 
overcome this problem. In the literature some ideas for control-group designs were discussed. 
For example, wait-list groups, attention-control groups or including a non-exercise 
intervention (24). In the PETRA study a non-exercise control group (progressive muscle 
relaxation) was selected, given the long intervention period. When communicating with the 
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participants, we always point out that our relaxation program is an intervention too in that we 
are interested in. We therefore hope that patients in the control group do not feel 
disadvantaged and consequently may start to exercise by themselves.  
A more methodological limitation is that we did not use our physical performance data 
assessed with gold-standard assessment procedures (CPET and isometric/ isokinetic muscle 
strength measurement) for the regression models of adherence and contamination as these 
assessment procedures were not performed at two included measurement time points 
(discharge and day 100). Therefore, we decided to use the data from the 6-minute-walk test 
and hand-held dynamometer instead, so that we could include all time-points in our analysis. 
These assessments procedures have proven to be reliable and are frequently used in this 
population (27-30).  
Current research questions in the field of exercise in cancer patients/ survivors include the 
need for more personalized exercise prescriptions, and information on dose-response 
relationships. The review by Buffart et al. summarized the currently available exercise 
guidelines for cancer survivors and concluded that these guidelines were rather generic and 
more information was needed to improve these recommendations (31). Thus, it is 
recommended to use exercise prescriptions developed for healthy adults, as described in 
chapter 4. To our knowledge, we were the first group, who compared these exercise 
prescriptions in terms of endurance training intensity with data driven from a cancer 
population. Our analyses revealed that given intensities may not meet targeted intensity 
classes prior to and 180 days after allo-HCT, therefore when using the current guidelines 
exercise intensity may be over- or underestimated. This is not only a problem when 
prescribing endurance exercise, but also when comparing previous training studies, because 
the targeted intensity in the different studies might have been quite different. As constituted in 
chapter 4, it is of great relevance to improve exercise prescription in cancer patients, but our 
data show as well that there is a large variation in observed values representing the different 
intensity classes. We therefore suggest, that optimal individually tailored exercise prescription 
can only be determined from an objective evaluation of the individual’s acute response to 
exercise (CPET), general intensity recommendations remain universal in nature and should 
not be used in studies. To improve exercise prescription in hematological cancer patients, we 
provided a table, similar to the table from ACSM, with exercise intensities derived from allo-
HCT patients (see chapter 4). This table can be used to define, for example, moderate or 
vigorous intensity. Furthermore, by using the tables, exercise intensities applied in different 
studies can be compared, even when studies used different parameters for intensity 
prescription (e.g. %HRR or %Pmax). Some previous studies in the HCT setting relied on 
equations (e.g. 220-age) to determine training intensity (2, 10, 32). However, our results show 
that this approach results in very imprecise values too and should not be recommended. It 
needs to be noted that our exercise test protocol was not ideal for patients with less physical 
capacity because of a relatively high first stage (50 watts, see discussion chapter 4). Just 
recently, a German working group developed a proposal to harmonize assessment procedures 
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in the oncological setting. Within these recommendations a more appropriate CPET protocol 
is proposed which will be used for future studies (33). Moreover, our findings regarding the 
different intensities showed up to be consistent in other cancer populations. Our group 
performed the same analysis in a population with 52 breast cancer patients after chemotherapy 
and could demonstrate that the ACSM classification in this population is only valid when 
%HRmax is used. Using %HRR resulted in a considerably too high exercise intensity, and 
using %VO2max in too low intensities (results not part of this thesis) (34). Defining precise 
intensity classes is key when more sophisticated questions are to be addressed, for example 
dose-response modulations.  
First RCTs were conducted to examine dose-response modulations in cancer populations. In 
the CARE-Trial, an RCT including 301 breast cancer patients during chemotherapy, a 
standard dose exercise program (25-30 min aerobic exercise 2 times per week) was compared 
to a higher dose (50-60 min per week) and a combined intervention (50-60 min aerobic and 
resistance exercise per week). The higher exercise dose was associated with better PROs, for 
example pain and other physical aspects, in breast cancer patients during chemotherapy; 
however, there were no differences between groups for the primary endpoint physical 
functioning (35). Though, in this study the exercise intensity, determined at percentages from 
VO2max, was the same in all groups. The exercise dose was different only in terms of exercise 
duration and type of exercise performed. Nevertheless, the prescribed intensity classes in the 
CARE-Trial correspond to our findings of exercise intensities in breast cancer patients (34, 
35). However, in a study with healthy sedentary adults, for example, a more appropriate 
design was used: Different exercise intensities (moderate vs. high intensity) were determined 
by 45-55% of HRR for moderate, and 65-75% HRR for high intensity (36). However, next 
generation studies are on the way comparing the effects of different endurance exercise 
intensities in cancer patients. For example, Jones et al. are conducting an RCT in 174 
postmenopausal women following primary therapy and comparing supervised moderate-
intensity aerobic training (150 min/ week 60-70% VO2peak) to supervised high-intensity 
training (150 min/week 60 – 100% VO2peak) for 18 weeks. A third group performs stretching 
exercise for comparison. The primary outcome is VO2peak (37).  
The different available guidelines for exercise prescription in cancer patients recommend to 
individually tailor exercise programs to the needs and current health status of the patients. An 
interesting study further underlines the need for more research in this area. The researchers 
examined if the current guidelines such as the ACSM guidelines for cancer survivors could be 
used to prescribe unsupervised exercise in 251 non-metastatic colon cancer survivors six 
months after completing curative treatment. They found out that it was only possible in 21% 
of survivors (or 42% when excluding survivors with common co-morbidities e.g. diabetes and 
hypertension). The authors concluded that guidelines for cancer survivors might also require 
other services such as supervision and staff with knowledge to appropriately tailor exercise. 
Furthermore, they pointed out that more research on safety, contraindications and adverse 
events (risk and harms) would enhance the likelihood of physicians to prescribe or 
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recommend exercise (38). However, this study was a retrospective study, and no information 
is available if the survivors were able to follow the guidelines. This examination points out 
that more studies are needed to enhance exercise prescriptions and that information on how to 
individualize exercise programs is lacking. Moreover, it is not clear which factors are 
important to consider when prescribing exercise in cancer patients and which factors may 
explain exercise response in cancer patients. Hereby, baseline physical fitness might be an 
essential aspect. 
In the non-cancer population, long established evidence from large cohort studies shows that 
low fitness is an independent predictor of mortality in men and women. Additionally, fit 
subjects with further known risk factors like smoking, elevated blood pressure, elevated 
cholesterol level had lower adjusted death rates than subjects with low fitness (39). For 
example, in a prospective cohort study in 9,777 men the gain in fitness parameters was 
associated with a 44% reduction in mortality risk (40), and an improvement of 3.5ml/kg/min 
maximum oxygen uptake has been found to improvement in survival by 12% (41). 
Furthermore, there is indisputable evidence that regular physical activity contributes to the 
prevention of several chronic diseases, e.g. cardiovascular diseases (42). In cancer patients 
first evidence suggests that the physical performance seems to have an important influence on 
clinical outcomes, such as survival. For example in patients with metastatic non-small cell 
lung cancer functional capacity, measured via 6-minute-walk test or CPET, was an 
independent predictor of survival. It contributed to an improved risk stratification and was 
therefore suggested to complement traditional prognostic markers (43, 44). Additionally, a 
cohort study in 32 patients prior allogeneic or autologous HCT showed a higher risk of 
mortality in patients who had less than 16ml/kg/min VO2 uptake (45), and the survival data of 
our first RCT also suggest that physical fitness is a protective factor against all-cause 
mortality and non-relapse mortality (3). 
To our knowledge, no study so far investigated a possible different response to exercise in 
cancer patient groups with different fitness levels. This information would help to understand 
the mechanisms of exercise in cancer patients during treatment. Since fitness plays such an 
important role regarding mortality in non-cancer subjects, and first evidence underlines 
similar effects also for some cancer populations, we performed a retrospective analysis of the 
experimental group of the first RCT (4), investigating the different training responses of 
different patients classified as fit (chapter 2). Results show that the individual response 
between fit and unfit groups was significantly different, with more benefit for initial unfit 
patients. Therefore, the results support the general recommendation to individually tailor the 
exercise prescription. Furthermore, the results show that even patients with low physical 
performance can safely exercise throughout the intensive treatment period of allo-HCT. This 
finding is of utmost importance, since exercise is often not recommended in these patients, 
and first studies in cancer patients and allo-HCT patients show a possible association of 
physical fitness prior allo-HCT and survival (see above). The methodological drawback of a 
retrospective analysis was discussed in chapter 2. Some questions, however, remain to be 
General Discussion 
 
 
65 
 
answered. It seems that in unfit patients the intensity of exercise prescription was appropriate, 
whereas in fit patients the dose of exercise might have been not high enough to obtain positive 
effects on the physical level. Interestingly, the adherence of both groups was similar, bearing 
in mind, that adherence was measured in sessions per week. Unfortunately, we cannot give 
further details on exercise duration or exercise intensity achieved. Intensity was determined 
by the patients using the BORG RPE scale (16), however, we do not know if targeted exercise 
intensity was reached. Therefore, it might be that fitter patients exercised at an individually 
lower intensity level, not reaching the optimal training load to achieve optimal effects. When 
we compared the fit exercise group to the control group, there was no significant difference, 
but a positive trend in favor of the exercise group. Nevertheless, it needs to be noted that the 
groups for these comparisons were quite small, influencing the non-significant finding. When 
looking at the graphical distribution of both groups (see chapter 2, figure 3), the exercising fit 
patients were superior to the control group patients. 
A review in non-cancer populations addressed the question of inter-individual variation in 
exercise response to regular exercise training and showed that subjects can have individual 
differences in responsiveness. Age, sex and ethnic origin were no major determinants of 
responsiveness, whereas pre-training level had considerable impact in some cases (46). In the 
HERITAGE family study where healthy individuals exercised at the same level of %VO2max 
intensity, it was suggested that the variation in training response may be partly explained by 
genetic components (47). Furthermore, the DREW study included 464 healthy post-
menopausal women to examine predictors of exercise non-response (measured VO2max) after 
6 months of training (intensity 50% VO2max). Despite high adherence (~92%) there was a 
large amount of variability. Predictor of VO2max non-response was (among others) baseline 
VO2max value. Thus, women who were initially less fit had greater changes of improving their 
VO2max (48). However, this result was not surprisingly, since 50% VO2max intensity is 
relatively low, and as described earlier, in more fitter subjects the exercise intensity needs to 
be more intense.  
In the previously mentioned CARE-Trail in breast cancer patients, moderators of exercise 
response were analyzed too, and fitter patients were more likely to benefit from higher-dose 
exercise, whereas less fit patients showed no benefits of higher dose exercise. Moreover, in 
accordance with our results, no interaction effect of fatigue and patient reported physical 
function could be observed in this study (49). These results support our finding that the 
exercise dose needs to be individually determined dependent on the baseline fitness in order 
to obtain an optimal effect for an individual patient. Furthermore, regarding a more 
methodological consideration, baseline fitness should be considered as a stratification variable 
in future studies. A meta-analysis examined the dose-response relationship regarding 
psychological outcomes, e.g. fatigue and quality of life, in breast cancer patients. The authors 
found that studies that applied a lower dose moderate exercise (<12MET h/week, ~90-120 
min) were more efficacious in reducing fatigue than studies that investigated higher exercise 
doses. However, to improve quality of life outcomes, studies with higher dose exercise (>20 
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MET h/week) were more efficient (50). Interestingly, we could not find an association 
between baseline fitness mediated exercise response and PROs in our study (chapter 2). With 
respect to quality of life outcomes during treatment, the actual Cochrane review also suggests 
that more intense exercise interventions (moderate/ vigorous intensity versus mild-intensity) 
were also more effective (51). These results emphasize the need for future dose-response 
studies. 
 
6.3 Conclusion and clinical implications 
The ultimate goal should be that exercise is prescribed as a routine part in hematological 
cancer patients or generally in cancer treatment. To meet this aim, we need further 
information about tolerability and positive effects of conducted exercise programs throughout 
the whole cancer trajectory. To interpret previous results adequately, it is of importance to 
distinguish between efficacy trials and effectiveness trials, thus, considering the studied 
population in more detail. The PETRA study achieved a high recruitment rate (73%), 
indicating a representative sample. Beside a detailed description of the intervention program, 
detailed adherence data according to the FITT formula enables reproducibility and translation 
of programs into clinical care. The PETRA study accomplished this target when describing in 
detail the frequency, duration and the exercise mode performed in different treatment periods 
during and after treatment. Such detailed description will also be crucial when analyzing more 
sophisticated questions, e.g. dose-response modulations. Adherence was with 66 to 77% (89 
to 199 min/ week) acceptable. Determinants of adherence provide important information on 
interaction of different physical, social, behavioral and medical factors with exercise 
participation. This information gives insight knowledge for designing exercise programs, on 
how to personalize programs and on how to target specific subgroups. Our results suggest a 
focus on problems regarding fatigue and physical performance when designing exercise 
programs in order to improve adherence. Furthermore, we think that including more 
comprehensive treatment data such as previous chemotherapy modalities, type of disease and 
co-morbidities, would be valuable in this kind of analysis. A closer look on activities 
performed in the control group revealed a serious problem of exercise contamination in the 
PETRA study. A large proportion of control group patients were physically active 180 days 
after transplantation (54% sport activity, 89% regular walking). Further analysis of group 
comparisons will illustrate to what extend this will have an impact on intention-to-treat 
analysis. Since contamination received little attention in RCTs, it is not clear how 
contamination influenced results in previous studies. Therefore, future studies should focus 
more on a possible contamination effect, and new strategies for control group designs are 
needed.  
Even though exercise guidelines for cancer patients exist, these recommendations remain 
rather general and adopt exercise guidelines developed for healthy subjects. A comparison of 
intensity classes for endurance training prescription revealed that the commonly used 
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guidelines are not valid in hematological cancer patients (prior to and 180 days after allo-
HCT) and would result in over- or underestimation of exercise intensity. The tables created 
can be used not only for exercise prescription, but also for comparison of different exercise 
intensities performed in other studies. Furthermore, these tables provide a basis for dose-
response studies. The analysis of the different exercise responses in patients with different 
initial fitness levels revealed that patients who were physically de-conditioned prior 
transplantation benefited more from exercise during and after allo-HCT. This result is of high 
clinical importance, since evidence of a possible association between initial fitness and 
survival after allo-HCT exists. Moreover, these data show that exercise is feasible even in de-
conditioned patients and suggest focusing more on this patient group. Moreover, the data 
underline the importance to individually tailor exercise prescription depended on current 
fitness status, and the need to identify individuals who may benefit in particular or who need 
special attention.  
 
6.4 Future Directions 
Results of previous research and results of this thesis underline the great potential of exercise 
in hematological cancer patients. However, further important research areas need to be 
considered in future trials.  
 
Pre-Training 
Given the low physical performance of allo-HCT patients already prior transplantation and 
the possible association with higher post-transplant mortality in initially unfit patients, the 
time point prior HCT seems to be an important research area. It appears to be essential to start 
an individualized exercise program as early as possible. This concept already proves 
feasibility in lung cancer patients, where exercise was implemented during waiting time for 
surgical resection (52). The results of this thesis support this idea of pre-training with the 
following aspects: we proved that unfit patients can exercise safely and are more likely to 
benefit from exercise (gain during treatment) than more fitter patients. The results also show 
that physical fitness seems to be an important determinant for adherence and contamination 
after allo-HCT, therefore an enhancement of physical activity in this period may be important. 
We could also demonstrate in our first study that an exercise program prior transplantation is 
feasible (4). This pre-training approach would complement the traditional rehabilitation 
procedure and implement an additional preparation period. This would ensure a 
comprehensive care throughout the whole PEACE framework. However, implementing 
exercise prior allo-HCT will be even more challenging because time from decision for allo-
HCT to transplantation is short and patients are often still under treatment. On the other hand, 
the preparation for transplantation is associated with many clinical examinations, providing a 
possibility to get in close and frequent contact with the patients. 
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Exercise Delivery 
Given the high frequency of hospital visits prior to and after allo-HCT, integration of exercise 
programs into standard hospital care seems to be practicable. One idea would be to extend our 
home-based exercise program during outpatient periods to a partly supervised program. This 
would ensure a closer monitoring and better adaption of exercise dose to clinical status. 
Additionally, more focus on exercise intensity could be given. This is an important 
consideration since the results of this thesis suggest that in fitter patients the training load of 
the mainly home-based self-directed exercise program might not have been high enough to 
obtain the same positive effects as in the unfit patients. In addition, more mechanistic 
questions regarding dose-response effects could be studied. Additionally, in this thesis, 
endurance exercise intensity classes for hematological cancer patients were defined. These 
intensity classes could be applied and further tested in supervised sessions. Interestingly, a 
recent RCT in 61 lung cancer patients after surgery proved the feasibility of a high intensity 
exercise program (80-95% HRmax) in combination with resistance exercises. Positive results 
were seen for different outcomes, including VO2max, muscle strength, muscle mass and quality 
of life (53). One small pilot study examined an outpatient exercise program during treatment 
for acute leukemia, but the program only comprised supervised sessions. However, the 
adherence was with 73% relatively high, suggesting that this kind of intervention will be 
feasible (54). An RCT in 70 patients is currently ongoing to prove these pilot findings in a 12- 
week intervention (55).  
Improving Adherence 
The adherence rates of the PETRA study show, that home-based programs over a longer 
duration are feasible and acceptable. Further analysis of the data will show how effective the 
program is on a physical and psychosocial level. The experience with the first included 153 
patients illustrates that a highly flexible exercise program is necessary. The exercise program 
needs to be performed outpatient at home as well as inpatient in the patient room, when 
patients are readmitted to hospital. In our study we ensured supervised exercise sessions in 
such cases, also when patients were on a different ward. In some circumstances, we could use 
an exercise room from the physiotherapy department (with resistance training machines and 
cycle ergometers), which was very well accepted by the patients. Therefore, incorporating 
further supervised exercise sessions during outpatient visits might be a promising adjunct that 
will help to build a bridge between home-based activities and hospital-based supervised 
exercise training. Another idea to improve adherence and to make interventions more 
interesting for the individual patient is to provide a referral to an exercise facility close to the 
patient’s home. This approach was partly tested in the PETRA study using the OnkoActiv 
Network, developed by the working group Physical Activity, Exercise and Cancer at the NCT. 
Furthermore, an internet-based training platform could be another tool to expand the training 
possibilities. Within the PETRA study such a platform was developed. Using this platform, an 
adaptive exercise program, feedback on training progress and the possibility to contact a study 
therapist is provided online. This platform was pilot-tested within the PETRA study as well, 
and proved good acceptability (56). 
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Taken into account the individual preferences, physical conditions, exercise history and travel 
issues a broad concept is needed, including different exercise opportunities. Only this ensures 
to match the needs and preferences of the individual patient to an optimal individualized 
exercise program and will result in appropriate adherence. Furthermore, variation and 
adoption of exercise prescription and regular communication to physician/ oncologist must be 
standard practice to ensure safety and a successful exercise program. Interestingly, a large 
multicenter prospective study in 711 patients before allogeneic or autologous transplantation 
concluded that brief exercise counselling prior transplantation had no effect on physical 
activity after transplantation or other outcomes such as quality of life (57). These data 
underline that there is a high need for exercise programs, guided by exercise experts and as 
part of clinical care, in particular for such a challenging population. 
Basic research 
Beside more research on health science and the integration of programs in clinical praxis 
(effectiveness trials), more mechanistic questions need to be studied. A recent publication of 
our group described the current level of evidence regarding possible physiologic and 
molecular mechanisms of exercise as preliminary (58). Within the PETRA study blood 
samples are drawn (and stored for further analysis) and a detailed documentation of GvHD 
occurrence, localization and severity is implemented in a highly standardized manner. This 
will be a unique opportunity to examine the interaction of exercise/ physical activity and 
immune markers, known to cause inflammation and GvHD. Previous studies in allo-HCT 
either did not include the treatment period in which chronic GvHD plays a role, or excluded 
patients with GvHD. Therefore, information on a possible interaction of exercise with chronic 
GvHD is unknown. Interestingly, first experimental studies in mouse-models established the 
hypothesis that exercise might influence the severity of chronic GvHD and survival positively 
by modulating an immune response (IL-4, TNF-α, CD4 lymphocytes) (59, 60). However, the 
sample was very small and the results have to be interpreted with caution. Yet, data in humans 
are not available. When looking deeper into this possible relationship, it will be of great 
importance to have detailed adherence data to consider a possible dose-response relationship. 
This will be important because there might be a possible non-linear relationship, indicating 
that a very high exercise dose might have negative effect on GvHD (61). Another interesting 
and less studied topic is to gain more insight into possible mechanisms on biomarker level 
regarding cancer-related fatigue. Recently, this topic was considered as high-priority research 
area (62). Here, the PETRA study will have great opportunities to study the interaction 
between inflammation and fatigue in a longitudinal pattern within an exercise intervention 
trial. 
Effects of Exercise on Side-Effects of Cancer Treatment 
Novel, innovative treatment regimens, such as immunomodulatory drugs (e.g. thalidomide, 
lenalidomid, bortezomib) and traditional chemotherapeutic agents, such as vincristine, 
cisplatin and methotrexat have led to improved outcomes in hematologic cancer patients, but 
are frequently associated with a dose-limiting peripheral neuropathy (CPIN) (63-65). CPIN is 
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caused by a structural and functional damage to nerve fibers. A first RCT in lymphoma 
patients could show promising results of sensorimotor training on quality of life and CPIN 
symptoms (66). Since CPIN is a side-effect not only affecting particular cancer entities, but 
affecting also groups of patients who receive certain treatment regimens, it may be more 
appropriate to study the effect of exercise on these patient groups with high risk of CPIN, 
independent of the type of cancer. A first consideration in this direction was done by 
Wiskemann & Scharhag-Rosenberger from our group. They introduced the side-effect-
oriented therapy pathway concept as a model to prescribe exercise on the basis of current 
evidence (67). Particularly in hematological cancer patients it seems valuable to further 
translate this approach into research, since a lot of different cancer entities exist and 
sometimes patient groups are quite small. In our two studies this approach was partly adopted 
when including patients with different entities (e.g. leukemia, lymphoma), but following the 
same treatment concept (allo-HCT), resulting in the same side-effects (e.g. GvHD).  
To pursue this idea further, beside CPIN, another research area that will be important in 
hematological cancer patients in the future is the effect of exercise on cardiotoxicity. Many 
chemotherapeutic agents, known to cause damage in the heart muscle, are frequently used in 
hematological cancers (e.g. doxorubicin, daunorubicin, cyclophospamide, idarubicin, and 
clofarabin). Antracyclines containing chemotherapy regimens are associated in a dose-
dependent mode with left ventricular dysfunction (68). In these settings, aerobic exercise 
might be a powerful tool because it may improve systolic and diastolic function as well as 
general exercise tolerance (69). Whereas most studies investigated protective effects of 
exercise on cardiac damage in animal models (mice and rat studies) (70), there is only one 
study in humans that investigated cardiac function following exercise intervention during 
chemotherapy treatment for breast cancer, but with inconclusive results (71). Also molecular 
targeted therapeutics can have cardiotoxic effects which may be prevented by aerobic exercise 
(72). 
Exercise in High-Risk Groups 
Implementing exercise interventions in multiple myeloma patients is an additional challenge 
due to an extensive bone destruction process associated with a high fracture risk (73). We 
faced this problem when including multiple myeloma patients in the PETRA study. 
Furthermore, a frequent side-effect of different treatment regimens used is osteoporosis (74, 
75). Therefore, more information is needed regarding not only on the stability of bone 
structure when performing exercise, but also on a possible interaction of bone destruction 
processes and exercise (resistance training). A first RCT in 106 postmenopausal non-
metastatic and non-osteoporotic breast cancer patients could demonstrate that a one-year 
resistance and impact (jump) exercise could prevent bone loss of the lumbar spine (76). 
Moreover, an RCT examined the feasibility of resistance training (isometric) in 60 patients 
with bone metastases (without fracture risk) under radiation therapy. Results were promising, 
indicating less pain and better physical function. Interestingly, no progression of metastases 
was seen in the experimental group after 3 months, whereas progression was evident in 17% 
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of control group patients (77). In the PETRA study we included 18 patients with multiple 
myeloma so far and a subgroup analysis will be performed in the future to examine if our 
mixed intervention program will have had any benefit regarding characteristic side-effects, for 
instance pain. 
In conclusion, this thesis established a basis for further research questions, including ideas for 
future studies, enhanced targeted exercise delivery, innovative research questions regarding 
effects of exercise on cancer treatment complications and basic scientific approaches to 
understand mechanisms. In the view of the vast potential of exercise in this broad scope of 
applications it becomes increasingly important to build up multidisciplinary research teams 
and integrate exercise science into clinical patient care. Starting from this thesis, a new study 
is being planned, investigating a pre-training approach in allo HCT patients.  
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